Aspirin for the Prevention of Transplant Renal Artery Stenosis: The Role of Age Factor

Aspirin for the Prevention of Transplant Renal Artery Stenosis: The Role of Age Factor | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Aspirin for the Prevention of Transplant Renal Artery Stenosis: The Role of Age Factor Xiangyong Tian, Xueyu Li, Wenjing Duan, Jingge Zhao, Xiaoqiang Wu, and 11 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8822867/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 8 You are reading this latest preprint version Abstract Transplant renal artery stenosis (TRAS) is a potentially serious complication following kidney transplantation. Low-dose aspirin has been proposed as a preventive strategy due to its antiplatelet and vascular protective effects. In this study, we retrospectively analyzed kidney transplant recipients at our center from January 2018 to December 2021. Patients were categorized into an aspirin group (n = 169) and a control group (n = 232). Initially diagnosed TRAS (id-TRAS) was diagnosed by Doppler ultrasound; confirmed TRAS (c-TRAS) by digital subtraction angiography. Id-TRAS incidence was similar between groups (14.20% vs. 15.95%), but c-TRAS was significantly lower with aspirin (2.96% vs. 7.76%; P = 0.041). ROC analysis identified 38 years as the optimal cutoff for TRAS risk,and patients were divided into two groups: ＜ 38 years and ≥ 38 years.After controlling for ages, the incidence of c-TRAS showed a statistically significant difference (P = 0.028). After controlling for aspirin use, the incidence rates of id-TRAS and c-TRAS differed significantly across age groups (P = 0.001; P ＜ 0.001). Kaplan-Meier analysis demonstrated that patients aged ＜ 38 years receiving aspirin had the lowest cumulative risk for both id-TRAS and c-TRAS, with statistically significant intergroup differences (log-rank P = 0.016; P = 0.006). Univariate Cox regression identified several risk factors for TRAS. Subsequent multivariate Cox regression revealed that aspirin use reduced the risk of id-TRAS and c-TRAS by 56% (HR = 0.44, 95% CI: 0.26 - 0.76, P = 0.003) and 73% (HR = 0.27, 95% CI: 0.10 - 0.74, P = 0.011), respectively. In contrast, age ≥ 38 years conferred a 1.91-fold and 2.84-fold increased risk for id-TRAS (HR = 1.91, 95% CI: 1.13 - 3.22, P = 0.015) and c-TRAS (HR = 2.84, 95% CI: 1.18 - 6.81, P = 0.020). Bleeding events were more frequent in the aspirin group (P = 0.016), with lower platelet aggregation at 3 months (P ＜ 0.001). In conclusion, low-dose aspirin appears to lower the incidence of c-TRAS, especially in younger recipients, while predisposing older patients to a higher risk of bleeding. These results emphasize the importance of individualized risk-benefit evaluation in clinical decision-making. Kidney transplantation Transplant renal artery stenosis Aspirin Figures Figure 1 Figure 2 Introduction For patients with end-stage renal disease (ESRD) who are candidates for kidney transplantation, the survival benefits of transplantation over long-term dialysis are well-established, offering both improved quality of life and prolonged survival 1 , 2 . Transplant renal artery stenosis (TRAS) is a vascular complication after renal transplantation, which was first reported in 1973 3 . The prevalence of TRAS varies widely, ranging from 0.6% to 25% 4–8 . Several factors contribute to the development of TRAS, including immune responses, atherosclerosis, cytomegalovirus infection, prolonged cold ischemia of the donor kidney, and surgical factors 7 , 9 – 13 . Early onset of TRAS is often associated with vascular injury during surgery or acute rejection 14 , 15 , while late onset is typically related to atherosclerosis, chronic rejection, or infection 13 , 16 . These factors can damage endothelial cells, leading to upregulation of endothelial adhesion molecules, which in turn promotes the adhesion and activation of platelets and leukocytes. The activation of these blood cells results in the release of a variety of chemokines and growth factors 17 – 20 , which further triggers inflammation and vascular remodeling, ultimately leading to fibrotic changes in the affected vessels, which manifest as intimal hyperplasia. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) widely used as an analgesic, anti-inflammatory, and antithrombotic agent 21 , 22 . Low-dose aspirin reduces the risk of thrombosis by irreversibly inhibiting platelet cyclooxygenase, thereby blocking thromboxane A2 production and subsequently preventing platelet activation and aggregation 23 . Additionally, aspirin has been shown to possess anti-atherosclerotic properties, inhibit abnormal proliferation of smooth muscle cells, and protect vascular endothelial cells 24 – 27 . Given its mechanism of action and the pathophysiology of vascular endothelial injury in TRAS, aspirin represents a potential preventive approach. Moreover, a previous prospective clinical trial at our center has provided preliminary evidence that early post-transplantation administration of low-dose aspirin can reduce the risk of TRAS 28 . However, Studies have shown that aging is associated with increased oxidative stress and a chronic inflammatory response 29 , 30 . The release of inflammatory mediators and excess reactive oxygen species (ROS) can damage vascular endothelial cells 31 , 32 . Furthermore, oxidative stress reduces the bioavailability of endothelial-derived nitric oxide (NO), contributing to age-related attenuation of endothelium-dependent vasodilation, increased vasoconstriction, and impaired tissue perfusion 33 . Consequently, the potential age-related differences in the efficacy of aspirin for preventing TRAS have not been adequately addressed. Therefore, the main purpose of this study is to investigate the impact of age on the preventive effect of low-dose aspirin for TRAS, and provide evidence to guide individualized clinical therapy. Materials and Methods This is a retrospective study of kidney transplant recipients at Henan Provincial People's Hospital between January 2018 and December 2021. All kidney transplants were performed by the same surgical team. Study population This was a single-center retrospective cohort study that consecutively enrolled adults (≥ 18 years old) who underwent kidney transplantation at Zhengzhou University People's Hospital between January 2018 and December 2021.The overall cohort had to meet the following general inclusion criteria: (1) survival with the transplanted kidney for ≥ 3 months with stable renal function, defined as serum creatinine ≤ 1.5 times the baseline value within the first 3 months post-transplant; (2) No severe rejection (Banff classification ≥ grade II) or graft failure within 3 months after transplantation; (3) No severe systemic infections, active malignancies, or autoimmune diseases; (4) Not recipients of multi-organ transplantation or previous non-renal organ transplantation; (5) Availability of complete clinical and follow-up data. Based on post-transplant antiplatelet therapy, patients were further divided into two groups: (1) Aspirin group: received continuous low-dose aspirin (oral aspirin within 2 weeks, 100 mg/day) for ≥ 3 months after surgery, with no concurrent use of other antiplatelet or anticoagulant drugs. (2) Control group: did not receive aspirin or any other antiplatelet/anticoagulant therapy after surgery and had no contraindications to aspirin (e.g., allergy, active bleeding, severe gastrointestinal ulcers). During the study period, a total of 464 patients underwent kidney transplantation. According to the above criteria, 63 patients were excluded, and 401 patients were finally included in the analysis, with 169 in the aspirin group and 232 in the control group. To avoid potential bias from arbitrary age intervals, we determined the optimal age cut-off for the study by plotting the receiver operating characteristic (ROC) curve of age versus the occurrence of TRAS in the study population. The optimal cut-off value was identified as 38 years. Both the aspirin and control groups were further divided into < 38 and ≥ 38 years of age subgroups. This cutoff was selected based on the study cohort's data distribution and should be considered exploratory, requiring external validation in future studies [Figure 1 ]. Study design and interventions Patients in both groups received a standard immunosuppressive regimen, consisting of induction with anti-thymocyte globulin (Thymoglobulin, Genzyme/Sanofi, France), followed by maintenance therapy with tacrolimus (Deliverf, Astellas, Japan), mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), and prednisolone (Xianju, Zhejiang, China) to maintain immunosuppression. After transplantation, tacrolimus was administered orally at a dose of 0.05 mg/kg twice daily. The tacrolimus dose was adjusted to maintain a blood concentration between 6 and 8 ng/mL. MMF was dosed at 750 mg twice daily, or alternatively, MPS was administered at 540 mg twice daily. Methylprednisolone was given as a single dose at the time of transplantation, followed by 500 mg, 300 mg, 200 mg, and 80 mg on postoperative days 1 to 4. Afterward, oral prednisolone was initiated in place of methylprednisolone, starting at a dose of 50 mg per day, which was subsequently tapered to a maintenance dose of 10 mg per day. Diagnosis and treatment of TRAS Doppler ultrasound (DUS) is a cost-effective, non-invasive imaging modality and serves as the primary tool for the initial screening and follow-up of TRAS. The diagnostic criteria for DUS include a peak systolic velocity (PSV) > 200 cm/s in the grafted renal artery and a ratio of the PSV of the renal artery to the PSV of the interlobar artery > 9.1. 34 We define patients who are diagnosed with TRAS by the above imaging tests and can be stabilised by conservative treatment as initially diagnosed TRAS (id-TRAS). Digital subtraction angiography (DSA) is the gold standard for TRAS diagnosis, with lumen stenosis rate ≥ 50% serving as the diagnostic criterion 35 . Although DSA provides precise diagnostic information, it is invasive, expensive, and associated with potential complications, such as hematoma, pseudoaneurysm, arterial entrapment, and thromboembolism 36 . All of which pose risks to the transplanted kidney. Therefore, DSA is typically reserved for cases where dynamic observation of id-TRAS patients is insufficient. DSA is performed if the patients develop persistent hypertension, decreased urine output, unexplained deterioration of renal function, or edema.. When DSA confirms TRAS, the patient is classified as having confirmed TRAS (c-TRAS), which is generally treated with percutaneous transluminal angioplasty (PTA), with or without stenting. The calculation of renal artery stenosis rate conformed to NASCET standard as follows: lumen stenosis rate = (normal diameter of the distal end of the stenosis-narrowest diameter of the stenotic segment) / (normal diameter of the distal end of the stenosis) 37 . Primary and secondary endpoints The primary endpoint of our study was the incidence of id-TRAS and c-TRAS among kidney transplant recipients. Secondary endpoints included the degree and location of renal artery stenosis in the transplanted kidney, changes in kidney function, biochemical blood markers, lipid levels, and C-reactive protein levels. Follow-up Follow-up visits were scheduled weekly for the first month after transplantation, monthly for the next 5 months, and every 2 months thereafter. If there was any change in the patient’s condition, the patient was instructed to contact our center for additional follow-up visits. During each visit, the following tests were performed: blood test, urine test, assessment of kidney function, liver function tests, lipid analysis, tacrolimus drug concentration, and DUS of the transplanted kidney. Statistical analysis Values are expressed as the mean ± standard deviation (SD) for normally distributed continuous variables, the median (interquartile range) for non-normally distributed variables, and percentages for categorical variables. Between-group comparisons of baseline characteristics and stenosis were performed using the Pearson chi-square test or the Mann-Whitney U test, as appropriate. Cumulative event rates for the primary diagnostic endpoints of id-TRAS and c-TRAS were calculated using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HR) were estimated using Cox regression modeling. In this study, covariates for the multivariate Cox regression model were selected based on their significance in the univariate analysis. Specifically, variables with a P -value < 0.05 in the univariate analysis were considered for inclusion in the multivariate model. Stratified chi-square tests were used to control for potential confounding factors and analyze differences in TRAS (id-TRAS and c-TRAS) incidence across different groups. Intergroup comparisons of clinical adverse event rates were conducted using Pearson's chi-square test, continuity-corrected chi-square test, or Fisher’s exact test, depending on the data characteristics. Comparisons of laboratory indicators between the two groups were performed using Mann-Whitney U test or independent samples t -test. All statistical analyses were performed using R version 3.6.0 software (R Foundation for Statistical Computing, Vienna, Austria). A P -value < 0.05 was considered statistically significant. Results Baseline characteristics There were no statistically significant differences between the control group (n = 232) and the aspirin group (n = 169) regarding gender, age, duration of dialysis, primary disease, comorbidities, infectious diseases, or the use of statins ( P > 0.05). However, significant differences were observed between the two groups in terms of renal artery anastomosis method and graft type ( P < 0.05) [Table 1 ]. Table 1 Baseline characteristics of the study patients Characteristic Aspirin group ( n = 169) Control group ( n = 232) Statistical values P -value Sex 0.230 0.632 Male 138 (81.66) 185 (79.74) Female 31 (18.34) 47 (20.26) Age (year) 36.00 (30.00, 44.50) 35.00 (30.00, 42.00) 1.359 0.174 * Ages < 38 ≥ 38 98 (57.99) 71 (42.01) 147 (63.36) 85 (36.64) 1.188 0.276 Dialysis time (month) 12.00 (6.00, 24.00) 12.00 (6.00, 24.00) -0.28 0.781 * Primary disease 4.27 0.511 Glomerulonephritis 50 (29.59) 68 (29.31) Hypertensive nephropathy 12 (7.10) 11 (4.74) Diabetic nephropathy 3 (1.78) 11 (4.74) Polycystic kidney 3 (1.78) 4 (1.72) Others 9 (5.33) 8 (3.45) Unknown 92 (54.44) 130 (56.03) Combined diseases 0.23 0.892 Only Hypertension 145 (85.80) 197 (84.91) Hypertension༆Diabetes 9 (5.33) 15 (6.46) None 15 (8.88) 20 (8.62) Infectious diseases 0.65 0.421 HBV / HCV / Syphilis 160 (94.67) 215 (92.67) None 9 (5.33) 17 (7.33) Renal arterial anastomosis 22.28 < 0.001 Internal iliac artery 98 (57.99) 185 (79.74) External iliac artery 71 (42.01) 47 (20.26) Allograft type 13.30 < 0.001 Deceased 104 (61.54) 100 (43.10) Living 65 (38.46) 132 (56.90) Statins or not after transplantion 0.17 0.68 Yes 89 (52.66) 127 (54.74) No 80 (47.34) 105 (45.26) Baseline patient characteristics are presented as numbers (%) for categorical variables or median (interquartile range) for continuous variables. *Refers to Mann–Whitney U test, and others were tested by Pearson χ2 test. HBV: Hepatitis B virus; HCV: Hepatitis C virus. Comparison of TRAS During a median follow-up period of 61 months, 61 patients (61/401, 15.21%) developed id-TRAS: 24 (24/169, 14.20%) in the aspirin group and 37 (37/232, 15.95%) in the control group. There was no statistically significant difference between the aspirin and control groups in terms of the incidence of id-TRAS, luminal stenosis rate, stenotic location, or duration from engraftment to id-TRAS ( P > 0.05). However, the differences in the incidence of c-TRAS, luminal stenosis rate, and stenotic location between the two groups were statistically significant ( P 0.05) [Table 2 ]. Table 2 The occurrence of TRAS in both groups Variables Aspirin group ( n = 169) Control group ( n = 232) Statistical values P -value id-TRAS 24 (14.20) 37 (15.95) 0.23 0.630 Lumen stenosis rate 50.00 (46.16, 56.96) 50.00 (45.83, 62.26) −0.12 0.906 * Stenotic location 0.40 0.525 Anastomosis 12 (50.00) 15 (41.67) Proximal end of anastomosis 12 (50.00) 21 (58.33) Duration from transplant to TRAS (days) 119.00 (71.50, 160.50) 106.00 (72.50, 182.00) −0.63 0.530 * c-TRAS 5 (2.96) 18 (7.76) 4.167 0.041 Lumen stenosis rate 50.00 (47.09, 73.60) 80.00 (53.96, 90.00) -2.06 0.037 * Stenotic location - 0.031 † Anastomosis 4 (80.00) 4 (22.2) Proximal end of anastomosis 1 (20.00) 14 (77.8) Duration from transplant to c-TRAS (days) 174.00 (92.50, 291.00) 172.00 (96.50, 211.25) -0.26 0.801 * Duration from id-TRAS to c-TRAS (days) 26.00 (19.00, 170.00) 49.50 (3.75, 124.50) -0.15 0.914 * Continuous variables are presented as median (interquartile range) and categorical variables as numbers (%). *Refers to Mann-Whitney U test, † Represents Fisher’s exact test, and others were tested by Pearson χ2 test. c-TRAS: Confirmed TRAS; id-TRAS: Initially diagnosed TRAS; TRAS: Transplant renal artery stenosis. Comparison of TRAS by age group After controlling for age, there was no statistically significant difference in id-TRAS incidence between the aspirin group and the control group ( P > 0.05), while a significant difference was observed in c-TRAS incidence ( P = 0.028) [Table 3 ]. After controlling for aspirin use, significant differences were observed in the incidence rates of id-TRAS and c-TRAS across different age groups (P = 0.001; P < 0.001) [Table 4 ] Table 3 Comparison of TRAS Between the Aspirin Group and the Control Group After Controlling for Age Factors Ages Aspirin id-TRAS Statistical values P -value c-TRAS Statistical values P -value Yes No Yes No < 38 years old Yes 8 90 0.439 0.508 & 1 97 4.815 0.028 & No 18 129 7 140 ≥ 38 years old Yes 16 55 4 67 No 19 66 11 74 & refers to Cochran-Mantel-Haenszel exact probability test. c-TRAS: Confirmed TRAS; id-TRAS: Initially diagnosed TRAS; TRAS: Transplant renal artery stenosis. Table 4 Comparison of TRAS Across Different Age Groups After Controlling for Aspirin Factors Aspirin Ages id-TRAS Statistical values P -value c-TRAS Statistical values P -value Yes No Yes No Yes < 38 years old 8 90 10.496 0.0012 & 1 97 7.855 0.00051 & ≥ 38 years old 16 55 4 67 No < 38 years old 18 129 7 140 ≥ 38 years old 19 66 11 74 & refers to Cochran-Mantel-Haenszel exact probability test. c-TRAS: Confirmed TRAS; id-TRAS: Initially diagnosed TRAS; TRAS: Transplant renal artery stenosis. Kaplan-Meier curves for the incidence of id-TRAS and c-TRAS Results indicate that patients aged ≥ 38 years had a higher cumulative risk of id-TRAS regardless of aspirin use, while those aged < 38 years who took aspirin had the lowest cumulative risk. Intergroup comparisons showed statistically significant differences [log-rank P = 0.016, Fig. 2 A]. Similarly, the cumulative risk of developing c-TRAS was lowest among aspirin users aged < 38 years and highest among non-aspirin users aged ≥ 38 years, with a statistically significant difference between groups [log-rank P = 0.006, Fig. 2 B]. Univariate and multivariate COX analyses of id-TRAS and c-TRAS Univariate analysis of TRAS risk in the aspirin and control groups revealed that high-risk factors for id-TRAS included non-aspirin use, age ≥ 38 years, deceased donor kidney, statin therapy, and low lymphocyte count ( P < 0.05). High-risk factors for c-TRAS included age ≥ 38 years, high blood urea nitrogen, and low lymphocyte count ( P < 0.05) [Table 5 ]. For id-TRAS patients, variables with P < 0.05 in univariate analysis were included in a multivariate Cox regression model Results showed that, when other factors remained constant, the risk ratio for id-TRAS occurrence in the aspirin group was 56% lower than in the control group ( P = 0.003); When other factors remained constant, patients aged ≥ 38 years had a 1.91-fold higher risk of id-TRAS compared to those < 38 years ( P = 0.015); When other factors remained constant, patients using statins had a 3.31 times higher risk of id-TRAS occurrence compared to non-users ( P < 0.001); When other factors remained constant, patients with low lymphocyte counts had a 2.31 times higher risk of id-TRAS occurrence compared to patients with normal counts ( P = 0.002). For c-TRAS patients, variables with P < 0.05 in univariate analysis were included in a multivariate Cox regression model. Results showed that, when other factors were held constant, the HR for c-TRAS occurrence in the aspirin group was 73% lower than in the control group ( P = 0.011); When other factors remained constant, patients aged ≥ 38 years had a 2.84-fold higher risk of c-TRAS compared to those < 38 years ( P = 0.020); When other factors remained constant, patients with high blood urea nitrogen had a 3.17-fold higher risk of c-TRAS compared to normal patients ( P = 0.037); When other factors remained constant, patients with low lymphocyte counts had a 4.04 times higher risk of developing c-TRAS compared to patients with normal counts ( P = 0.003) [Table 6 ]. Table 5 Univariate COX Regression Analysis of id-TRAS and c-TRAS Variables id-TRAS c-TRAS HR(95% CI) P -value HR(95% CI) P -value Aspirin No 1.00 (Reference) 1.00 (Reference) Yes 0.57 (0.34–0.97) 0.036 0.37 (0.14–1.01) 0.051 Sex Male 1.00 (Reference) 1.00 (Reference) Female 1.11 (0.60–2.05) 0.746 1.17 (0.44–3.16) 0.755 Ages (year) < 38 1.00 (Reference) 1.00 (Reference) ≥ 38 1.96 (1.18–3.26) 0.010 3.03 (1.29–7.15) 0.011 Combined diseases None 1.00 (Reference) 1.00 (Reference) Only Hypertension 0.82 (0.35–1.91) 0.637 2.07 (0.28–15.42) 0.478 Hypertension༆Diabetes 2.04 (0.72–5.75) 0.178 2.96 (0.27–32.69) 0.375 Infectious diseases None 1.00 (Reference) 1.00 (Reference) HBV / HCV / Syphilis 0.79 (0.25–2.54) 0.695 1.41 (0.33–6.02) 0.641 Renal arterial anastomosis Internal iliac artery 1.00 (Reference) 1.00 (Reference) External iliac artery 1.18 (0.70–2.00) 0.536 1.06 (0.44–2.57) 0.900 Allograft type Deceased 1.00 (Reference) 1.00 (Reference) Living 0.57 (0.33–0.99) 0.046 0.66 (0.29–1.53) 0.335 Statins or not after transplantion No 1.00 (Reference) 1.00 (Reference) Yes 2.83 (1.65–4.86) < 0.001 1.08 (0.48–2.44) 0.860 Creatinine (µmol/L) Normal (58–110) 1.00 (Reference) 1.00 (Reference) Low 0.00 (0.00 - Inf) 0.996 0.00 (0.00 - Inf) 0.998 High 0.96 (0.51–1.81) 0.897 1.63 (0.64–4.13) 0.304 Urea nitrogen (mmol/L) Normal (3.20–7.10) 1.00 (Reference) 1.00 (Reference) High 1.47 (0.87–2.49) 0.146 3.74 (1.27–10.10) 0.016 Neutrophils (⋅10 9/ L) Normal (1.80–6.30) 1.00 (Reference) 1.00 (Reference) Low 1.05 (0.45–2.46) 0.905 1.08 (0.253–4.632) 0.915 High 0.93 (0.33–2.58) 0.884 0.42 (0.056–3.132) 0.398 Platelets (⋅10 9/ L) Normal (3.20–7.10) 1.00 (Reference) 1.00 (Reference) Low 1.55 (0.70–3.43) 0.275 1.31 (0.31–5.59) 0.714 High 0.70 (0.10–5.10) 0.727 0.00 (0.00 - Inf) 0.997 Lymphocytes (⋅10 9/ L) Normal (3.20–7.10) 1.00 (Reference) 1.00 (Reference) Low 2.26 (1.34–3.80) 0.002 4.53 (1.85–11.12) < 0.001 High 1.90 (0.57–6.27) 0.295 2.49 (0.31–20.21) 0.394 C-reactive protein (mg/L) Normal (3.20–7.10) 1.00 (Reference) 1.00 (Reference) High 2.02 (0.28–14.72) 0.486 0.00 (0.00 - Inf) 0.997 PAR (%) Normal (3.20–7.10) 1.00 (Reference) 1.00 (Reference) Low 0.85 (0.48–1.49) 0.561 1.31 (0.52–3.33) 0.569 High 0.93 (0.39–2.22) 0.875 1.88 (0.61–5.84) 0.273 Cholesterol (mmol/L) Normal (3.20–7.10) 1.00 (Reference) 1.00 (Reference) Low 1.55 (0.56–4.33) 0.402 0.64 (0.09–4.79) 0.665 High 0.98 (0.46–2.07) 0.949 1.14 (0.34–3.86) 0.830 Triglycerides (mmol/L) Normal (3.20–7.10) 1.00 (Reference) 1.00 (Reference) High 0.98 (0.46–2.07) 0.556 1.18 (0.52–2.68) 0.691 HDL-C (mmol/L) Normal (3.20–7.10) 1.00 (Reference) 1.00 (Reference) Abnormal 0.75 (0.42–1.32) 0.312 1.24 (0.53–2.92) 0.625 LDL-C (mmol/L) Normal (3.20–7.10) 1.00 (Reference) 1.00 (Reference) Abnormal 0.29 (0.04–2.11) 0.222 0.92 (0.12–6.85) 0.938 HBV: Hepatitis B virus; HCV: Hepatitis C virus; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; PAR: Platelet aggregation rate; CI: Confidence interval; c-TRAS: Confirmed TRAS; id-TRAS: Initially diagnosed TRAS; TRAS: Transplant renal artery stenosis. Table 6 Multivariable COX Regression Analysis of id-TRAS and c-TRAS Variables id-TRAS c-TRAS HR (95% CI) P -value HR (95% CI) P -value Aspirin No Yes 1.00 (Reference) 0.44 (0.26–0.76) 0.003 1.00 (Reference) 0.27 (0.10–0.74) 0.011 Ages < 38 ≥ 38 1.00 (Reference) 1.91 (1.13–3.22) 0.015 1.00 (Reference) 2.84 (1.18–6.81) 0.020 Statins or not after transplantion No Yes 1.00 (Reference) 3.31 (1.89–5.80) < 0.001 - - Urea nitrogen (mmol/L) Normal (3.20–7.10) - - 1.00 (Reference) 0.037 High 3.17 (1.07–9.41) Lymphocytes (⋅10 9/ L) Normal (3.20–7.10) 1.00 (Reference) 1.00 (Reference) Low 2.31 (1.36–3.93) 0.002 4.04 (1.63–10.02) 0.003 High 2.47 (0.69–8.80) 0.163 4.31 (0.51–36.56) 0.180 c-TRAS: Confirmed TRAS; HR: Hazard ratio; id-TRAS: Initially diagnosed TRAS; TRAS: Transplant renal artery stenosis; LDL-C: Low-density lipoprotein cholesterol; CI: Confidence interval. Clinical adverse events The difference in the total number of clinical adverse reactions and the incidence of haemorrhagic disorders between the two groups was statistically significant ( P 0.05) [Table 7 ]. Table 7 Comparison of clinical adverse events among the kidney transplantation recipients between aspirin group and control group Characteristic Aspirin group ( n = 169) Control group ( n = 232) Statistical values P -value Total clinical adverse events, n (%) 36 (21.30) 30 (12.93) 4.98 0.026 Hemorrhagic diseases, n (%) 27 (15.98) 19 (8.19) 5.84 0.016 Gastrointestinal ulcer 6 (22.22) 5 (26.32) - 0.481 † Gastrointestinal bleeding 3(11.11)) 1 (5.26 Conjunctival hemorrhage 6 (22.22) 1 (5.26) Cerebral hemorrhage 3 (11.11) 2 (10.53) Uterine bleeding 4 (14.81) 7 (36.84) Hematuria 2 (7.41) 1 (5.26) Epistaxis 2 (7.41) 0 (0.00) Thyroid bleeding 0 (0.00) 1 (5.26) Bronchorrhagia 1 (3.70) 1 (5.26) Infarct diseases, n (%) 7 (4.14) 6 (2.59) 0.75 0.385 Cerebral infarction 4 (57.14) 5 (83.33) - 0.559† Myocardial infarction 3 (42.86) 1 (16.67) Thrombotic diseases, n (%) 2 (1.18) 5 (2.16) - 0.704 † Venous thrombosis 2 (100.00) 4 (80.00) - > 0.999 † Arterial thrombosis 0 (0.00) 1 (20.00) Graft failure, n (%) 19 (11.24) 22 (9.48) 0.33 0.566 Death, n (%) 3 (1.78) 10 (4.31) 2.00 0.157 Values are presented as numbers (%). †Refers to Fisher’s exact test, others were tested by Pearson χ2 test. Laboratory indicators The differences in creatinine, urea nitrogen, neutrophils, platelets, lymphocytes, C-reactive protein,, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were not statistically significant in the two groups at 3 months after kidney transplantation ( P > 0.05). The two groups showed statistically significant differences in both the Platelet aggregation rate (PAR) and cholesterol levels. ( P < 0.05) [Table 8 ]. Table 8 Comparison of laboratory indicators of the kidney transplantation recipients at 3 months after renal transplantation Variables Aspirin group ( n = 169) Control group ( n = 232) Statistical values P -value Creatinine, n (%) 0.188 † Normal 142 (84.02) 185 (79.74) Low 1 (0.59) 0 (0) High 26 (15.39) 47 (20.26) Urea nitrogen, n (%) 1.18 0.277 Normal 68 (40.24) 106 (45.69) High 101 (59.76) 126 (54.31) Neutrophils, n (%) 1.764 0.414 Normal 136 (80.47) 196 (84.48) Low 16 (9.47) 14 (6.03) High 17 (10.06) 22 (9.48) Platelets, n (%) 0.667 † Normal 155 (91.72) 211 (90.95) Low 12 (7.10) 15 (6.47) High 2 (1.18) 6 (2.59) Lymphocytes, n (%) 4.259 0.119 Normal 99 (58.58) 159 (68.53) Low 63 (37.28) 65 (28.02) High 7 (4.14) 8 (3.45) C-reactive protein, n (%) 0.000 1.000 Normal 168 (99.41) 230 (99.14) High 1 (0.59) 2 (0.86) PAR, n (%) 50.01 < 0.001 Normal 88 (52.07) 158 (68.10) Low 75 (44.38) 35 (15.09) High 6 (3.55) 39 (16.81) Cholesterol, n (%) 9.736 0.008 Normal 150 (88.76) 178 (76.72) Low 8 (4.73) 19 (8.19) High 11 (6.51) 35 (15.09) Triglycerides, n (%) 0.586 0.444 Normal 99 (58.58) 127 (54.74) High 70 (41.42) 105 (45.26) HDL-C, n (%) 1.216 0.270 Normal 113 (66.86) 167 (71.98) Abnormal 56 (33.14) 65 (28.02) LDL-C, n (%) 3.639 0.056 Normal 165 (97.63) 217 (93.53) Abnormal 4 (2.37) 15 (6.47) Continuous variables are presented as median (interquartile range) or mean ± standard deviation. † Refers to Fisher’s exact test, others were tested by Pearson χ2 test. PAR: Platelet aggregation rate; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol. Discussion This study aimed to investigate the impact of age on the preventive efficacy of low-dose aspirin against TRAS. Although a previous prospective randomized controlled trial suggested that postoperative low-dose aspirin may reduce the risk of TRAS, the extent to which this preventive effect varies with age has not been clearly defined. 28 Therefore, we conducted a retrospective analysis with stringent inclusion and exclusion criteria to further explore this question. Given the retrospective, non-randomized design and potential for residual confounding, the observed associations should be interpreted cautiously as hypothesis-generating rather than definitive evidence of causality. In the present study, there were no significant differences in baseline characteristics between the two groups, except for renal artery anastomosis and graft type. In the subsequent univariate analysis, we found that deceased donor kidney was a risk factor for id-TRAS but not for c-TRAS, and renal arterial anastomosis was not a significant risk factor for TRAS ( P > 0.05).Previous studies have shown that the risk of TRAS is higher in deceased-donor kidney transplantation than in living-donor kidney transplantation. 4 , 5 However, baseline data indicated a higher rate of cadaveric transplantation in the aspirin group compared to the control group (61.54% vs 43.10%), yet the incidence of TRAS was lower in the aspirin group. This finding may indicate that aspirin plays a role in preventing and managing TRAS. Although there was no statistically significant difference in the incidence of id-TRAS between the two groups, the incidence of c-TRAS was significantly lower in the aspirin group than in the control group (2.96% vs 7.76%, P = 0.041), and patients with TRAS in the control group exhibited more severe luminal stenosis (P = 0.037). This further confirms that low-dose aspirin use is associated with a reduced incidence of c-TRAS, consistent with our previous findings.. 28 Furthermore, we classified the study subjects in both the aspirin and control groups into age subgroups (< 38 years and ≥ 38 years). In subgroup analysis, after controlling for the effect of aspirin, significant differences were observed in the incidence rates of id-TRAS ( P = 0.001) and c-TRAS ( P < 0.001) across different age groups, suggesting that age may influence the efficacy of aspirin in preventing TRAS. Survival curves revealed that patients aged ≥ 38 years had a higher cumulative risk of id-TRAS regardless of aspirin use, while those aged < 38 years who took aspirin had the lowest cumulative risk, with statistically significant differences between groups (log-rank P = 0.016). Survival analysis for c-TRAS patients revealed the lowest cumulative risk among aspirin users aged < 38 years and the highest cumulative risk among non-aspirin users aged ≥ 38 years, with a statistically significant difference between groups (log-rank P = 0.006). This further indicates that age is a key factor influencing aspirin efficacy. Given the limited number of c-TRAS events, the multivariable estimates for this outcome should be interpreted with caution due to potential model overfitting. Further univariate and multivariate analyses revealed that non-aspirin use, age ≥ 38 years, cadaveric transplantation, statin use, and low lymphocyte count were risk factors for id-TRAS. Age ≥ 38 years, elevated blood urea nitrogen, and low lymphocyte count were risk factors for c-TRAS. Multivariate Cox regression analysis revealed that aspirin use was associated with a reduced risk of TRAS. In contrast, several factors were identified as significant risk predictors for TRAS, including age ≥ 38 years, statin use, elevated blood urea nitrogen levels, and low lymphocyte counts. These findings suggest that while aspirin may offer a protective effect, other clinical variables, particularly those associated with kidney function and immune status, play crucial roles in determining TRAS risk. However, further research is needed to validate these associations and explore potential interactions between these factors in different patient populations. Patients receiving statins often have vascular plaques, advanced age, dyslipidemia, or a history of cardiovascular or cerebrovascular disease, potentially contributing to higher TRAS incidence. While aspirin has well-established benefits in preventing thrombosis, its use may increase the risk of hemorrhagic events, particularly gastrointestinal bleeding, and this risk is higher in older patients 38 – 41 . Clinical trials have reported an increased risk of bleeding with low-dose aspirin therapy 42 , 43 . These findings underscore the importance of carefully weighing the potential benefits and risks of aspirin use, especially in older patients. The decision to initiate aspirin therapy should be individualized, considering factors such as the patient’s underlying health, type of disease, and concurrent medications.. Our findings indicate that patients in the aspirin group experienced a higher incidence of bleeding-related clinical events compared to the control group (15.98% vs 8.19%, P = 0.016). Additionally, the aspirin group exhibited a higher overall incidence of clinical adverse events (21.30% vs 12.93%, P = 0.026), consistent with previous literature findings. However, this contradicts our earlier prospective study 28 , likely due to differences in enrollment periods and modifications to inclusion/exclusion criteria. Consequently, the benefits and risks of aspirin use in different renal transplant populations require comprehensive evaluation. When determining aspirin therapy, patient age, medical history, and a thorough risk-benefit assessment must be considered holistically. Significant differences were observed between the aspirin group and the control group at 3 months post-transplantation in terms of arachidonic acid-induced platelet aggregation rate ( P < 0.001) and cholesterol levels ( P = 0.008). consistent with findings from our prior prospective study 28 . It is hypothesized that aspirin may prevent TRAS by partially inhibiting microthrombus formation through anticoagulation and by preventing atherosclerosis via lipid profile improvement. Conclusions In this single-center cohort, administering low-dose aspirin post-transplant was associated with a lower incidence of c-TRAS, with the most pronounced protective effect observed in recipients aged < 38 years. However, aspirin use was also associated with an increased risk of bleeding, emphasizing the need for individualized risk-benefit evaluation. Limitations The main limitations of this study include its retrospective nature, the potential for unmeasured confounding factors, and the single-center design. Furthermore, the sample size was limited, and future validation with larger, multicenter studies is necessary to confirm these findings. Abbreviations ESRD end-stage renal disease TRAS transplant renal artery stenosis NSAID nonsteroidal anti-inflammatory drug ROS reactive oxygen species NO nitric oxide ROC receiver operating characteristic DUS Doppler ultrasound id-TRAS initially diagnosed TRAS PSA peak systolic velocity DSA digital subtraction angiography c-TRAS confirmed TRAS ATG anti-thymocyte globulin MMF mycophenolate mofetil MPS mycophenolate sodium CTA computed tomography angiography MRA magnetic resonance angiography PTA percutaneous transluminal angioplasty HBV Hepatitis B virus HCV Hepatitis C virus HR Hazard ratio PAR Platelet aggregation rate LDL-C low-density lipoprotein cholesterol LDL-C: Low-density lipoprotein cholesterol.. Declarations Ethics approval and consent to participate The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Henan Provincial People’s Hospital. Given the retrospective nature and use of anonymized data, informed consent was waived by the Ethics Committee. Transplantation studies statement All transplanted organs were obtained from voluntary donors with informed consent, in accordance with the relevant national and international regulations. No organs or tissues were procured from prisoners. The kidneys were procured from donors via the China Organ Transplantation Response System, and transplantations were performed at Henan Provincial People’s Hospital, Zhengzhou, China. Consent for publication Not applicable. Competing interests The authors declare that there are no competing interests associated with the manuscript. CRediT Author Contribution X.T., X.L., T.Y., and T.Q.: Conceptualization. W.D. and J.Z.: Methodology. X.W., G.C., X.J., Z.W., X.W., C.Z., Z.Y., and X.F.: Investigation. J.Z., X.T., X.L., and W.D.: Visualization. X.T. and X.L.: Writing—original draft. X.T., X.L., W.D., Q.L., and Q.F.: Writing—review & editing. X.T., X.J., and T.Y.: Funding acquisition. T.Y. and T.Q.: Supervision. Funding This work was supported by the Project of Science and Technology of Henan Province (Grant No. 232102310157), the Joint construction project of Henan Medical Science and technology research plan (Grant No. LHGJ20240029), the natural Science Foundation of Henan Province of China (Grant No. 242300421301), the Henan Province Medical Science and Technology Research (Joint Construction) Project (Grant No. LHG20220781). Author Contribution X.T., X.L., T.Y., and T.Q.: Conceptualization. W.D. and J.Z.: Methodology. X.W., G.C., X.J., Z.W., X.W., C.Z., Z.Y., and X.F.: Investigation. J.Z., X.T., X.L., and W.D.: Visualization. X.T. and X.L.: Writing—original draft. X.T., X.L., W.D., Q.L., and Q.F.: Writing—review & editing. X.T., X.J., and T.Y.: Funding acquisition. T.Y. and T.Q.: Supervision. Acknowledgements Not applicable. Data Availability Data from this study are available from the authors upon reasonable request. Please contact [email protected] to request data. Access to data may be subject to approval, confidentiality and ethical conditions. References Hariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. N Engl J Med Aug. 2021;19(8):729–43. 10.1056/NEJMra2014530 . Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med Dec. 1999;2(23):1725–30. 10.1056/nejm199912023412303 . Margules RM, Belzer FO, Kountz SL. Surgical correction of renovascular hypertension following renal allotransplantation. Arch Surg Jan. 1973;106(1):13–6. 10.1001/archsurg.1973.01350130017003 . Biederman DM, Fischman AM, Titano JJ, et al. Tailoring the endovascular management of transplant renal artery stenosis. Am J Transplant Apr. 2015;15(4):1039–49. 10.1111/ajt.13105 . Bruno S, Remuzzi G, Ruggenenti P. Transplant renal artery stenosis. J Am Soc Nephrol Jan. 2004;15(1):134–41. 10.1097/01.asn.0000099379.61001.f8 . Carpenter DJ, Mohan S, Ratner LE, Schlossberg P. Combined Percutaneous Transrenal and Transfemoral Endovascular Recanalization and Angioplastic Reconstruction of a Disrupted Transplant Renal Artery Stent: A Novel Salvage Technique. Am J Transplant Apr. 2017;17(4):1119–24. 10.1111/ajt.14115 . Hurst FP, Abbott KC, Neff RT, et al. Incidence, predictors and outcomes of transplant renal artery stenosis after kidney transplantation: analysis of USRDS. Am J Nephrol. 2009;30(5):459–67. 10.1159/000242431 . Willicombe M, Sandhu B, Brookes P, et al. Postanastomotic transplant renal artery stenosis: association with de novo class II donor-specific antibodies. Am J Transplant Jan. 2014;14(1):133–43. 10.1111/ajt.12531 . Aubert O, Kamar N, Vernerey D, et al. Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. Bmj Jul. 2015;31:351:h3557. 10.1136/bmj.h3557 . Audard V, Matignon M, Hemery F, et al. Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty. Am J Transplant Jan. 2006;6(1):95–9. 10.1111/j.1600-6143.2005.01136.x . Braga AF, Catto RC, Dalio MB, et al. Endovascular Approach to Transplant Renal Artery Stenosis. Ann Transplant Nov. 2015;24:20:698–706. 10.12659/aot.894867 . Kamali K, Abbasi MA, Behzadi AH, Mortazavi A, Bastani B. Incidence and risk factors of transplant renal artery stenosis in living unrelated donor renal transplantation. J Ren Care Sep. 2010;36(3):149–52. 10.1111/j.1755-6686.2010.00188.x . Kobayashi K, Censullo ML, Rossman LL, Kyriakides PN, Kahan BD, Cohen AM. Interventional radiologic management of renal transplant dysfunction: indications, limitations, and technical considerations. Radiographics Jul-Aug. 2007;27(4):1109–30. 10.1148/rg.274065135 . Martelli E, Enea I, Zamboni M, et al. Focus on the Most Common Paucisymptomatic Vasculopathic Population, from Diagnosis to Secondary Prevention of Complications. Diagnostics (Basel) Jul. 2023;13(14). 10.3390/diagnostics13142356 . Yang S, Kang J, Park KW, et al. Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks. J Am Coll Cardiol Oct. 2023;17(16):1565–78. 10.1016/j.jacc.2023.07.031 . Nasserala JC, Oliveira CM, Cerqueira JB et al. Artery Stenosis of the Renal Graft: Experience of a Center of Northeastern Brazil. Transplant Proc . Jan-Feb. 2016;48(1):74–80. 10.1016/j.transproceed.2015.11.004 Elmously A, Stern JR, Greenberg J, et al. Carbon Dioxide Angiography in the Treatment of Transplant Renal Artery Stenosis. Ann Vasc Surg Feb. 2020;63:198–203. 10.1016/j.avsg.2019.08.085 . Gaddikeri S, Mitsumori L, Vaidya S, Hippe DS, Bhargava P, Dighe MK. Comparing the diagnostic accuracy of contrast-enhanced computed tomographic angiography and gadolinium-enhanced magnetic resonance angiography for the assessment of hemodynamically significant transplant renal artery stenosis. Curr Probl Diagn Radiol Jul-Aug. 2014;43(4):162–8. 10.1067/j.cpradiol.2014.03.001 . Nicholson ML, Yong C, Trotter PB, Grant L, Hosgood SA. Risk factors for transplant renal artery stenosis after live donor transplantation. Br J Surg Feb. 2019;106(3):199–205. 10.1002/bjs.10997 . Robinson KA, Kriegshauser JS, Dahiya N, Young SW, Czaplicki CD, Patel MD. Detection of transplant renal artery stenosis: determining normal velocities at the renal artery anastomosis. Abdom Radiol (NY) Jan. 2017;42(1):254–9. 10.1007/s00261-016-0876-7 . Aghayev A, Memon AA, Zheng S, Menard M, Siedlecki AM. Transplant renal artery and vein occlusion evaluated with ferumoxytol-enhanced magnetic resonance angiography. Clin Imaging Sep. 2021;77:142–6. 10.1016/j.clinimag.2021.02.022 . Visagie JL, Aruwajoye GS, van der Sluis R. Pharmacokinetics of aspirin: evaluating shortcomings in the literature. Expert Opin Drug Metab Toxicol Aug. 2024;20(8):727–40. 10.1080/17425255.2024.2386368 . Yusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. Jan 2021;21(3):216–28. 10.1056/NEJMoa2028220 . Chang H, Gelb BE, Stewart ZA, et al. Safety and Efficacy of Drug Eluting Stents for Treatment of Transplant Renal Artery Stenosis. Ann Vasc Surg Nov. 2022;87:245–53. 10.1016/j.avsg.2022.03.033 . Dickey KW, Durrani RJ. Does Endovascular Intervention for Transplant Renal Artery Stenosis Improve Outcomes at 10 Years? Radiology Feb. 2019;290(2):564–5. 10.1148/radiol.2018182252 . Hinojosa-Gonzalez DE, Salgado-Garza G, Torres-Martinez M, et al. Endovascular Treatment of Transplant Renal Artery Stenosis: A Systematic Review and Meta-analysis. J Endovasc Ther Apr. 2022;29(2):294–306. 10.1177/15266028211038593 . Patel U, Kumar S, Johnson OW, Jeon JH, Das R. Long-term Graft and Patient Survival after Percutaneous Angioplasty or Arterial Stent Placement for Transplant Renal Artery Stenosis: A 21-year Matched Cohort Study. Radiology Feb. 2019;290(2):555–63. 10.1148/radiol.2018181320 . Tian X, Ji B, Niu X et al. Efficacy and safety of low-dose aspirin on preventing transplant renal artery stenosis: a prospective randomized controlled trial. Chin Med J (Engl) . Mar 5. 2023;136(5):541–549. 10.1097/cm9.0000000000002574 Cevenini E, Monti D, Franceschi C. Inflamm-ageing. Curr Opin Clin Nutr Metab Care Jan. 2013;16(1):14–20. 10.1097/MCO.0b013e32835ada13 . Schöttker B, Saum KU, Jansen EH, et al. Oxidative stress markers and all-cause mortality at older age: a population-based cohort study. J Gerontol Biol Sci Med Sci Apr. 2015;70(4):518–24. 10.1093/gerona/glu111 . El-Mahdy MA, Abdelghany TM, Hemann C, et al. Chronic cigarette smoke exposure triggers a vicious cycle of leukocyte and endothelial-mediated oxidant stress that results in vascular dysfunction. Am J Physiol Heart Circ Physiol. Jul 2020;1(1):H51–65. 10.1152/ajpheart.00657.2019 . Kawaguchi Y, Kuwana M. Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis. Curr Opin Rheumatol Nov. 2023;1(6):309–16. 10.1097/bor.0000000000000959 . Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of Vascular Aging. Circ Res Sep. 2018;14(7):849–67. 10.1161/circresaha.118.311378 . Pan FS, Liu M, Luo J, et al. Transplant renal artery stenosis: Evaluation with contrast-enhanced ultrasound. Eur J Radiol May. 2017;90:42–9. 10.1016/j.ejrad.2017.02.031 . Wongpraparut N, Chaipruckmalakarn T, Tongdee T, et al. Long-term outcome of percutaneous transluminal renal angioplasty (PTRA) versus PTRA with stenting (PTRAS) in transplant renal artery stenosis. BMC Cardiovasc Disord Apr. 2021;26(1):212. 10.1186/s12872-021-02015-4 . Gunawardena T, Sharma H. Transplant Renal Artery Stenosis: Current Concepts. Exp Clin Transplant Dec. 2022;20(12):1049–57. 10.6002/ect.2022.0334 . Barnett HJM, Taylor DW, Haynes RB, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med Aug. 1991;15(7):445–53. 10.1056/nejm199108153250701 . Mahady SE, Margolis KL, Chan A, et al. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut Apr. 2021;70(4):717–24. 10.1136/gutjnl-2020-321585 . McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med Oct. 2018;18(16):1509–18. 10.1056/NEJMoa1805819 . Orkaby AR, Dufour AB, Yang L, et al. Long-Term Aspirin Use and Self-Reported Walking Speed in Older Men: The Physicians' Health Study. J Frailty Aging. 2022;11(1):12–7. 10.14283/jfa.2021.36 . Wang FM, Yebyo HG, Ballew SH, et al. Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention. Am J Prev Cardiol Mar. 2023;13:100468. 10.1016/j.ajpc.2023.100468 . McQuilten ZK, Thao LTP, Pasricha SR, et al. Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly: A Secondary Analysis of the Aspirin in Reducing Events in the Elderly Trial. Ann Intern Med. Jul 2023;176(7):913–21. 10.7326/m23-0675 . Zoungas S, Zhou Z, Owen AJ, et al. Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial. Lancet Diabetes Endocrinol Feb. 2024;12(2):98–106. 10.1016/s2213-8587(23)00327-3 . Additional Declarations No competing interests reported. Cite Share Download PDF Status: Under Review Version 1 posted Reviews received at journal 07 May, 2026 Reviewers agreed at journal 06 May, 2026 Reviewers agreed at journal 13 Apr, 2026 Reviewers invited by journal 26 Feb, 2026 Editor assigned by journal 24 Feb, 2026 Editor invited by journal 16 Feb, 2026 Submission checks completed at journal 15 Feb, 2026 First submitted to journal 15 Feb, 2026 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8822867","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":597460489,"identity":"3fadb23e-675c-494f-8934-12912375866a","order_by":0,"name":"Xiangyong Tian","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Xiangyong","middleName":"","lastName":"Tian","suffix":""},{"id":597460491,"identity":"22893597-73db-4264-b710-4339edee831b","order_by":1,"name":"Xueyu Li","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Xueyu","middleName":"","lastName":"Li","suffix":""},{"id":597460494,"identity":"103e7485-242e-400b-87f5-d8aff8d6f566","order_by":2,"name":"Wenjing Duan","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Wenjing","middleName":"","lastName":"Duan","suffix":""},{"id":597460495,"identity":"ecb8ea5b-0a70-4485-bbd2-04c406a46788","order_by":3,"name":"Jingge Zhao","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Jingge","middleName":"","lastName":"Zhao","suffix":""},{"id":597460500,"identity":"64e1a6d2-d52d-49d1-890c-374bd1d20361","order_by":4,"name":"Xiaoqiang Wu","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Xiaoqiang","middleName":"","lastName":"Wu","suffix":""},{"id":597460503,"identity":"5763d537-6358-4da1-8fd0-7168e47a0f34","order_by":5,"name":"Guanghui Cao","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Guanghui","middleName":"","lastName":"Cao","suffix":""},{"id":597460506,"identity":"82181644-4cb6-4af6-89c7-d881d2399ce5","order_by":6,"name":"Xin Jiang","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Xin","middleName":"","lastName":"Jiang","suffix":""},{"id":597460511,"identity":"ad0ed3f2-7ab4-4ad4-848f-973a301adab9","order_by":7,"name":"Zhiwei Wang","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Zhiwei","middleName":"","lastName":"Wang","suffix":""},{"id":597460514,"identity":"ce7b0674-5915-4ddb-9a4f-d6ea0a007de6","order_by":8,"name":"Xuan Wu","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Xuan","middleName":"","lastName":"Wu","suffix":""},{"id":597460518,"identity":"0aae2e8d-bc99-4306-a8b2-35dff706f0af","order_by":9,"name":"Chan Zhang","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Chan","middleName":"","lastName":"Zhang","suffix":""},{"id":597460521,"identity":"5852b4cf-3b18-422a-a586-4830df9b967c","order_by":10,"name":"Zhongnan Yang","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Zhongnan","middleName":"","lastName":"Yang","suffix":""},{"id":597460523,"identity":"07de938a-08f5-4143-b2c0-27eb4a8f4b13","order_by":11,"name":"Xiaobing Feng","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Xiaobing","middleName":"","lastName":"Feng","suffix":""},{"id":597460526,"identity":"ead230fd-6101-4124-9c40-8353cb941b3e","order_by":12,"name":"Qiankun Luo","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Qiankun","middleName":"","lastName":"Luo","suffix":""},{"id":597460530,"identity":"0bab1e9a-47f3-436c-bce0-c56a0a261143","order_by":13,"name":"Qiang Fu","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Qiang","middleName":"","lastName":"Fu","suffix":""},{"id":597460532,"identity":"b48d843a-8977-4562-94d7-4e8491dbcc1a","order_by":14,"name":"Tianzhong Yan","email":"","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Tianzhong","middleName":"","lastName":"Yan","suffix":""},{"id":597460538,"identity":"8a20a15b-7dad-438a-a465-71c1607e12bd","order_by":15,"name":"Tao Qin","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAzElEQVRIiWNgGAWjYJACiQowxXzgwIcfxGo5A6bYEg/O7CFNC4/xYQ42IpTLuzcfvHFwj40c/+yeD4cZeBjk+cUO4NdieOZYssWBZ2nGEnfObjhcYMFgOHN2AgEtM3LMpD8cOJy4QSJ3w+EZPAwJBreJ0CJx4MD/+g0SOQ8O87ARoUVeAqzlQIKBRA4DcVoMeEB+OZBsOONGmgEwkCUI+0W+HRhiBw7YyfPPSH784cMPG3l+aUK2HEDlS+BXDralgbCaUTAKRsEoGOkAAG+jSqYS4m0iAAAAAElFTkSuQmCC","orcid":"","institution":"Zhengzhou University People’s Hospital","correspondingAuthor":true,"prefix":"","firstName":"Tao","middleName":"","lastName":"Qin","suffix":""}],"badges":[],"createdAt":"2026-02-08 15:54:50","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8822867/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8822867/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":104170512,"identity":"db4ea01b-47ec-4c80-858c-09d1d883be1a","added_by":"auto","created_at":"2026-03-08 14:47:58","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":95841,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eFlow chart for inclusion of study participants\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-8822867/v1/c2ab3fb11d0486f3952fe4bc.png"},{"id":104779574,"identity":"6e9b4f2a-cd91-47f0-b0f0-3b6b9af567e5","added_by":"auto","created_at":"2026-03-17 07:42:29","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":123583,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eKaplan-Meier curve for incidence of id-TRAS (A) and c-TRAS (B). id-TRAS: Initially diagnosed TRAS; TRAS: Transplant renal artery stenosis; c-TRAS: Confirmed TRAS.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"floatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-8822867/v1/87f00f2373bef032fc095ac1.png"},{"id":105033504,"identity":"7fa614ee-3693-4ef7-955a-f43b045d146f","added_by":"auto","created_at":"2026-03-20 07:18:44","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2342962,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8822867/v1/c7463470-214a-4e13-9be7-e0425b5f87df.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Aspirin for the Prevention of Transplant Renal Artery Stenosis: The Role of Age Factor","fulltext":[{"header":"Introduction","content":"\u003cp\u003eFor patients with end-stage renal disease (ESRD) who are candidates for kidney transplantation, the survival benefits of transplantation over long-term dialysis are well-established, offering both improved quality of life and prolonged survival\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. Transplant renal artery stenosis (TRAS) is a vascular complication after renal transplantation, which was first reported in 1973\u003csup\u003e3\u003c/sup\u003e. The prevalence of TRAS varies widely, ranging from 0.6% to 25%\u003csup\u003e4\u0026ndash;8\u003c/sup\u003e. Several factors contribute to the development of TRAS, including immune responses, atherosclerosis, cytomegalovirus infection, prolonged cold ischemia of the donor kidney, and surgical factors\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e,\u003cspan additionalcitationids=\"CR10 CR11 CR12\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. Early onset of TRAS is often associated with vascular injury during surgery or acute rejection\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e,\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e, while late onset is typically related to atherosclerosis, chronic rejection, or infection\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e,\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e. These factors can damage endothelial cells, leading to upregulation of endothelial adhesion molecules, which in turn promotes the adhesion and activation of platelets and leukocytes. The activation of these blood cells results in the release of a variety of chemokines and growth factors\u003csup\u003e\u003cspan additionalcitationids=\"CR18 CR19\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e, which further triggers inflammation and vascular remodeling, ultimately leading to fibrotic changes in the affected vessels, which manifest as intimal hyperplasia.\u003c/p\u003e \u003cp\u003eAspirin is a nonsteroidal anti-inflammatory drug (NSAID) widely used as an analgesic, anti-inflammatory, and antithrombotic agent\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e,\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. Low-dose aspirin reduces the risk of thrombosis by irreversibly inhibiting platelet cyclooxygenase, thereby blocking thromboxane A2 production and subsequently preventing platelet activation and aggregation\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. Additionally, aspirin has been shown to possess anti-atherosclerotic properties, inhibit abnormal proliferation of smooth muscle cells, and protect vascular endothelial cells\u003csup\u003e\u003cspan additionalcitationids=\"CR25 CR26\" citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e. Given its mechanism of action and the pathophysiology of vascular endothelial injury in TRAS, aspirin represents a potential preventive approach. Moreover, a previous prospective clinical trial at our center has provided preliminary evidence that early post-transplantation administration of low-dose aspirin can reduce the risk of TRAS\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eHowever, Studies have shown that aging is associated with increased oxidative stress and a chronic inflammatory response\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e,\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. The release of inflammatory mediators and excess reactive oxygen species (ROS) can damage vascular endothelial cells\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e,\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e. Furthermore, oxidative stress reduces the bioavailability of endothelial-derived nitric oxide (NO), contributing to age-related attenuation of endothelium-dependent vasodilation, increased vasoconstriction, and impaired tissue perfusion\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e. Consequently, the potential age-related differences in the efficacy of aspirin for preventing TRAS have not been adequately addressed. Therefore, the main purpose of this study is to investigate the impact of age on the preventive effect of low-dose aspirin for TRAS, and provide evidence to guide individualized clinical therapy.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cp\u003eThis is a retrospective study of kidney transplant recipients at Henan Provincial People's Hospital between January 2018 and December 2021. All kidney transplants were performed by the same surgical team.\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy population\u003c/h2\u003e \u003cp\u003eThis was a single-center retrospective cohort study that consecutively enrolled adults (\u0026ge;\u0026thinsp;18 years old) who underwent kidney transplantation at Zhengzhou University People's Hospital between January 2018 and December 2021.The overall cohort had to meet the following general inclusion criteria: (1) survival with the transplanted kidney for \u0026ge;\u0026thinsp;3 months with stable renal function, defined as serum creatinine\u0026thinsp;\u0026le;\u0026thinsp;1.5 times the baseline value within the first 3 months post-transplant; (2) No severe rejection (Banff classification\u0026thinsp;\u0026ge;\u0026thinsp;grade II) or graft failure within 3 months after transplantation; (3) No severe systemic infections, active malignancies, or autoimmune diseases; (4) Not recipients of multi-organ transplantation or previous non-renal organ transplantation; (5) Availability of complete clinical and follow-up data.\u003c/p\u003e \u003cp\u003eBased on post-transplant antiplatelet therapy, patients were further divided into two groups: (1) Aspirin group: received continuous low-dose aspirin (oral aspirin within 2 weeks, 100 mg/day) for \u0026ge;\u0026thinsp;3 months after surgery, with no concurrent use of other antiplatelet or anticoagulant drugs. (2) Control group: did not receive aspirin or any other antiplatelet/anticoagulant therapy after surgery and had no contraindications to aspirin (e.g., allergy, active bleeding, severe gastrointestinal ulcers).\u003c/p\u003e \u003cp\u003eDuring the study period, a total of 464 patients underwent kidney transplantation. According to the above criteria, 63 patients were excluded, and 401 patients were finally included in the analysis, with 169 in the aspirin group and 232 in the control group. To avoid potential bias from arbitrary age intervals, we determined the optimal age cut-off for the study by plotting the receiver operating characteristic (ROC) curve of age versus the occurrence of TRAS in the study population. The optimal cut-off value was identified as 38 years. Both the aspirin and control groups were further divided into \u0026lt; 38 and \u0026ge;\u0026thinsp;38 years of age subgroups. This cutoff was selected based on the study cohort's data distribution and should be considered exploratory, requiring external validation in future studies [Figure \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eStudy design and interventions\u003c/h3\u003e\n\u003cp\u003e Patients in both groups received a standard immunosuppressive regimen, consisting of induction with anti-thymocyte globulin (Thymoglobulin, Genzyme/Sanofi, France), followed by maintenance therapy with tacrolimus (Deliverf, Astellas, Japan), mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), and prednisolone (Xianju, Zhejiang, China) to maintain immunosuppression. After transplantation, tacrolimus was administered orally at a dose of 0.05 mg/kg twice daily. The tacrolimus dose was adjusted to maintain a blood concentration between 6 and 8 ng/mL. MMF was dosed at 750 mg twice daily, or alternatively, MPS was administered at 540 mg twice daily. Methylprednisolone was given as a single dose at the time of transplantation, followed by 500 mg, 300 mg, 200 mg, and 80 mg on postoperative days 1 to 4. Afterward, oral prednisolone was initiated in place of methylprednisolone, starting at a dose of 50 mg per day, which was subsequently tapered to a maintenance dose of 10 mg per day.\u003c/p\u003e\n\u003ch3\u003eDiagnosis and treatment of TRAS\u003c/h3\u003e\n\u003cp\u003eDoppler ultrasound (DUS) is a cost-effective, non-invasive imaging modality and serves as the primary tool for the initial screening and follow-up of TRAS. The diagnostic criteria for DUS include a peak systolic velocity (PSV) \u0026gt; 200 cm/s in the grafted renal artery and a ratio of the PSV of the renal artery to the PSV of the interlobar artery \u0026gt; 9.1.\u003csup\u003e34\u003c/sup\u003e We define patients who are diagnosed with TRAS by the above imaging tests and can be stabilised by conservative treatment as initially diagnosed TRAS (id-TRAS). Digital subtraction angiography (DSA) is the gold standard for TRAS diagnosis, with lumen stenosis rate\u0026thinsp;\u0026ge;\u0026thinsp;50% serving as the diagnostic criterion\u003csup\u003e\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u003c/sup\u003e. Although DSA provides precise diagnostic information, it is invasive, expensive, and associated with potential complications, such as hematoma, pseudoaneurysm, arterial entrapment, and thromboembolism\u003csup\u003e\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e. All of which pose risks to the transplanted kidney. Therefore, DSA is typically reserved for cases where dynamic observation of id-TRAS patients is insufficient. DSA is performed if the patients develop persistent hypertension, decreased urine output, unexplained deterioration of renal function, or edema.. When DSA confirms TRAS, the patient is classified as having confirmed TRAS (c-TRAS), which is generally treated with percutaneous transluminal angioplasty (PTA), with or without stenting. The calculation of renal artery stenosis rate conformed to NASCET standard as follows: lumen stenosis rate = (normal diameter of the distal end of the stenosis-narrowest diameter of the stenotic segment) / (normal diameter of the distal end of the stenosis) \u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\n\u003ch3\u003ePrimary and secondary endpoints\u003c/h3\u003e\n\u003cp\u003eThe primary endpoint of our study was the incidence of id-TRAS and c-TRAS among kidney transplant recipients. Secondary endpoints included the degree and location of renal artery stenosis in the transplanted kidney, changes in kidney function, biochemical blood markers, lipid levels, and C-reactive protein levels.\u003c/p\u003e\n\u003ch3\u003eFollow-up\u003c/h3\u003e\n\u003cp\u003eFollow-up visits were scheduled weekly for the first month after transplantation, monthly for the next 5 months, and every 2 months thereafter. If there was any change in the patient\u0026rsquo;s condition, the patient was instructed to contact our center for additional follow-up visits. During each visit, the following tests were performed: blood test, urine test, assessment of kidney function, liver function tests, lipid analysis, tacrolimus drug concentration, and DUS of the transplanted kidney.\u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eValues are expressed as the mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation (SD) for normally distributed continuous variables, the median (interquartile range) for non-normally distributed variables, and percentages for categorical variables. Between-group comparisons of baseline characteristics and stenosis were performed using the Pearson chi-square test or the Mann-Whitney U test, as appropriate. Cumulative event rates for the primary diagnostic endpoints of id-TRAS and c-TRAS were calculated using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HR) were estimated using Cox regression modeling. In this study, covariates for the multivariate Cox regression model were selected based on their significance in the univariate analysis. Specifically, variables with a \u003cem\u003eP\u003c/em\u003e-value \u0026lt; 0.05 in the univariate analysis were considered for inclusion in the multivariate model. Stratified chi-square tests were used to control for potential confounding factors and analyze differences in TRAS (id-TRAS and c-TRAS) incidence across different groups. Intergroup comparisons of clinical adverse event rates were conducted using Pearson's chi-square test, continuity-corrected chi-square test, or Fisher\u0026rsquo;s exact test, depending on the data characteristics. Comparisons of laboratory indicators between the two groups were performed using Mann-Whitney U test or independent samples \u003cem\u003et\u003c/em\u003e-test. All statistical analyses were performed using R version 3.6.0 software (R Foundation for Statistical Computing, Vienna, Austria). A \u003cem\u003eP\u003c/em\u003e-value \u0026lt; 0.05 was considered statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eBaseline characteristics\u003c/h2\u003e \u003cp\u003eThere were no statistically significant differences between the control group (n\u0026thinsp;=\u0026thinsp;232) and the aspirin group (n\u0026thinsp;=\u0026thinsp;169) regarding gender, age, duration of dialysis, primary disease, comorbidities, infectious diseases, or the use of statins (\u003cem\u003eP\u003c/em\u003e \u0026gt; 0.05). However, significant differences were observed between the two groups in terms of renal artery anastomosis method and graft type (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05) [Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBaseline characteristics of the study patients\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCharacteristic\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAspirin group (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;169)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eControl group (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;232)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eStatistical values\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSex\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.230\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.632\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e138 (81.66)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e185 (79.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e31 (18.34)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e47 (20.26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAge (year)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e36.00 (30.00, 44.50)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e35.00 (30.00, 42.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.359\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.174\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAges\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u0026lt; 38\u003c/p\u003e \u003cp\u003e\u0026ge;\u0026thinsp;38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e98 (57.99)\u003c/p\u003e \u003cp\u003e71 (42.01)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e147 (63.36)\u003c/p\u003e \u003cp\u003e85 (36.64)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1.188\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.276\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDialysis time (month)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12.00 (6.00, 24.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e12.00 (6.00, 24.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e-0.28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.781\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePrimary disease\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e4.27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.511\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGlomerulonephritis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e50 (29.59)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e68 (29.31)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHypertensive nephropathy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12 (7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11 (4.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDiabetic nephropathy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3 (1.78)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11 (4.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePolycystic kidney\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3 (1.78)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4 (1.72)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOthers\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e9 (5.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8 (3.45)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUnknown\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e92 (54.44)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e130 (56.03)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCombined diseases\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.892\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOnly Hypertension\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e145 (85.80)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e197 (84.91)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHypertension༆Diabetes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e9 (5.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e15 (6.46)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNone\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e15 (8.88)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e20 (8.62)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eInfectious diseases\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.421\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHBV / HCV / Syphilis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e160 (94.67)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e215 (92.67)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNone\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e9 (5.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e17 (7.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eRenal arterial anastomosis\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e22.28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e\u0026lt; 0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eInternal iliac artery\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e98 (57.99)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e185 (79.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eExternal iliac artery\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e71 (42.01)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e47 (20.26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAllograft type\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e13.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e\u0026lt; 0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDeceased\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e104 (61.54)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e100 (43.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLiving\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e65 (38.46)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e132 (56.90)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eStatins or not after transplantion\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.68\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e89 (52.66)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e127 (54.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e80 (47.34)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e105 (45.26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003eBaseline patient characteristics are presented as numbers (%) for categorical variables or median (interquartile range) for continuous variables. *Refers to Mann\u0026ndash;Whitney U test, and others were tested by Pearson χ2 test. HBV: Hepatitis B virus; HCV: Hepatitis C virus.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eComparison of TRAS\u003c/h2\u003e \u003cp\u003eDuring a median follow-up period of 61 months, 61 patients (61/401, 15.21%) developed id-TRAS: 24 (24/169, 14.20%) in the aspirin group and 37 (37/232, 15.95%) in the control group. There was no statistically significant difference between the aspirin and control groups in terms of the incidence of id-TRAS, luminal stenosis rate, stenotic location, or duration from engraftment to id-TRAS (\u003cem\u003eP\u003c/em\u003e \u0026gt; 0.05). However, the differences in the incidence of c-TRAS, luminal stenosis rate, and stenotic location between the two groups were statistically significant (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05). The duration from transplant to c-TRAS and from id-TRAS to c-TRAS did not differ significantly between the two groups (\u003cem\u003eP\u003c/em\u003e \u0026gt; 0.05) [Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eThe occurrence of TRAS in both groups\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVariables\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAspirin group (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;169)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eControl group (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;232)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eStatistical values\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eid-TRAS\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e24 (14.20)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e37 (15.95)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.630\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLumen stenosis rate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e50.00 (46.16, 56.96)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e50.00 (45.83, 62.26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026minus;0.12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.906\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStenotic location\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.525\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAnastomosis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12 (50.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e15 (41.67)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eProximal end of anastomosis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12 (50.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e21 (58.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDuration from transplant to TRAS (days)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e119.00 (71.50, 160.50)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e106.00 (72.50, 182.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026minus;0.63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.530\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ec-TRAS\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e5 (2.96)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e18 (7.76)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.167\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.041\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLumen stenosis rate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e50.00 (47.09, 73.60)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e80.00 (53.96, 90.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-2.06\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.037\u003c/b\u003e\u003csup\u003e\u003cb\u003e*\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStenotic location\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.031\u003c/b\u003e\u0026dagger;\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAnastomosis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e4 (80.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4 (22.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eProximal end of anastomosis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1 (20.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e14 (77.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDuration from transplant to c-TRAS (days)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e174.00 (92.50, 291.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e172.00 (96.50, 211.25)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.801\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDuration from id-TRAS to c-TRAS (days)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e26.00 (19.00, 170.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e49.50 (3.75, 124.50)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-0.15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.914\u003csup\u003e*\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003eContinuous variables are presented as median (interquartile range) and categorical variables as numbers (%). *Refers to Mann-Whitney U test, \u003csup\u003e\u0026dagger;\u003c/sup\u003eRepresents Fisher\u0026rsquo;s exact test, and others were tested by Pearson χ2 test. c-TRAS: Confirmed TRAS; id-TRAS: Initially diagnosed TRAS; TRAS: Transplant renal artery stenosis.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eComparison of TRAS by age group\u003c/h2\u003e \u003cp\u003eAfter controlling for age, there was no statistically significant difference in id-TRAS incidence between the aspirin group and the control group (\u003cem\u003eP\u003c/em\u003e \u0026gt; 0.05), while a significant difference was observed in c-TRAS incidence (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.028) [Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e]. After controlling for aspirin use, significant differences were observed in the incidence rates of id-TRAS and c-TRAS across different age groups (P\u0026thinsp;=\u0026thinsp;0.001; \u003cem\u003eP\u003c/em\u003e \u0026lt; 0.001) [Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e]\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eComparison of TRAS Between the Aspirin Group and the Control Group After Controlling for Age Factors\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"10\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eAges\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eAspirin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003eid-TRAS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eStatistical values\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003ec-TRAS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eStatistical values\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u0026lt; 38 years old\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e0.439\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e0.508\u003csup\u003e\u0026amp;\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e97\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e4.815\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e\u003cb\u003e0.028\u003c/b\u003e\u003csup\u003e\u0026amp;\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e129\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e140\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;38 years old\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e67\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e74\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"10\"\u003e\u003csup\u003e\u003cb\u003e\u0026amp;\u003c/b\u003e\u003c/sup\u003erefers to Cochran-Mantel-Haenszel exact probability test. c-TRAS: Confirmed TRAS; id-TRAS: Initially diagnosed TRAS; TRAS: Transplant renal artery stenosis.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eComparison of TRAS Across Different Age Groups After Controlling for Aspirin Factors\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"10\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eAspirin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eAges\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003eid-TRAS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eStatistical values\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003ec-TRAS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eStatistical values\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt; 38 years old\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e10.496\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e\u003cb\u003e0.0012\u003c/b\u003e\u003csup\u003e\u0026amp;\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e97\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e7.855\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e\u003cb\u003e0.00051\u003c/b\u003e\u003csup\u003e\u0026amp;\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;38 years old\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e67\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt; 38 years old\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e129\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e140\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;38 years old\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e74\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"10\"\u003e\u003csup\u003e\u003cb\u003e\u0026amp;\u003c/b\u003e\u003c/sup\u003erefers to Cochran-Mantel-Haenszel exact probability test. c-TRAS: Confirmed TRAS; id-TRAS: Initially diagnosed TRAS; TRAS: Transplant renal artery stenosis.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eKaplan-Meier curves for the incidence of id-TRAS and c-TRAS\u003c/h2\u003e \u003cp\u003eResults indicate that patients aged\u0026thinsp;\u0026ge;\u0026thinsp;38 years had a higher cumulative risk of id-TRAS regardless of aspirin use, while those aged \u0026lt; 38 years who took aspirin had the lowest cumulative risk. Intergroup comparisons showed statistically significant differences [log-rank \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.016, Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA]. Similarly, the cumulative risk of developing c-TRAS was lowest among aspirin users aged \u0026lt; 38 years and highest among non-aspirin users aged\u0026thinsp;\u0026ge;\u0026thinsp;38 years, with a statistically significant difference between groups [log-rank \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.006, Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB].\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eUnivariate and multivariate COX analyses of id-TRAS and c-TRAS\u003c/h2\u003e \u003cp\u003eUnivariate analysis of TRAS risk in the aspirin and control groups revealed that high-risk factors for id-TRAS included non-aspirin use, age\u0026thinsp;\u0026ge;\u0026thinsp;38 years, deceased donor kidney, statin therapy, and low lymphocyte count (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05). High-risk factors for c-TRAS included age\u0026thinsp;\u0026ge;\u0026thinsp;38 years, high blood urea nitrogen, and low lymphocyte count (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05) [Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e]. For id-TRAS patients, variables with \u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05 in univariate analysis were included in a multivariate Cox regression model Results showed that, when other factors remained constant, the risk ratio for id-TRAS occurrence in the aspirin group was 56% lower than in the control group (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.003); When other factors remained constant, patients aged\u0026thinsp;\u0026ge;\u0026thinsp;38 years had a 1.91-fold higher risk of id-TRAS compared to those \u0026lt; 38 years (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.015); When other factors remained constant, patients using statins had a 3.31 times higher risk of id-TRAS occurrence compared to non-users (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001); When other factors remained constant, patients with low lymphocyte counts had a 2.31 times higher risk of id-TRAS occurrence compared to patients with normal counts (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.002). For c-TRAS patients, variables with \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05 in univariate analysis were included in a multivariate Cox regression model. Results showed that, when other factors were held constant, the HR for c-TRAS occurrence in the aspirin group was 73% lower than in the control group (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.011); When other factors remained constant, patients aged\u0026thinsp;\u0026ge;\u0026thinsp;38 years had a 2.84-fold higher risk of c-TRAS compared to those \u0026lt; 38 years (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.020); When other factors remained constant, patients with high blood urea nitrogen had a 3.17-fold higher risk of c-TRAS compared to normal patients (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.037); When other factors remained constant, patients with low lymphocyte counts had a 4.04 times higher risk of developing c-TRAS compared to patients with normal counts (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.003) [Table\u0026nbsp;\u003cspan refid=\"Tab6\" class=\"InternalRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eUnivariate COX Regression Analysis of id-TRAS and c-TRAS\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eVariables\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eid-TRAS\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003ec-TRAS\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHR(95% CI)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eHR(95% CI)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAspirin\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.57 (0.34\u0026ndash;0.97)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e0.036\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.37 (0.14\u0026ndash;1.01)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.051\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eSex\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.11 (0.60\u0026ndash;2.05)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.746\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.17 (0.44\u0026ndash;3.16)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.755\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAges (year)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026lt; 38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.96 (1.18\u0026ndash;3.26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e0.010\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.03 (1.29\u0026ndash;7.15)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.011\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCombined diseases\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNone\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOnly Hypertension\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.82 (0.35\u0026ndash;1.91)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.637\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.07 (0.28\u0026ndash;15.42)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.478\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHypertension༆Diabetes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.04 (0.72\u0026ndash;5.75)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.178\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.96 (0.27\u0026ndash;32.69)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.375\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eInfectious diseases\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNone\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHBV / HCV / Syphilis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.79 (0.25\u0026ndash;2.54)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.695\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.41 (0.33\u0026ndash;6.02)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.641\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eRenal arterial anastomosis\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eInternal iliac artery\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eExternal iliac artery\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.18 (0.70\u0026ndash;2.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.536\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.06 (0.44\u0026ndash;2.57)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.900\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAllograft type\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDeceased\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLiving\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.57 (0.33\u0026ndash;0.99)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e0.046\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.66 (0.29\u0026ndash;1.53)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.335\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eStatins or not after transplantion\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.83 (1.65\u0026ndash;4.86)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e\u0026lt; 0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.08 (0.48\u0026ndash;2.44)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.860\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCreatinine (\u0026micro;mol/L)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (58\u0026ndash;110)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.00 (0.00 - Inf)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.996\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.00 (0.00 - Inf)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.998\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.96 (0.51\u0026ndash;1.81)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.897\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.63 (0.64\u0026ndash;4.13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.304\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eUrea nitrogen (mmol/L)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (3.20\u0026ndash;7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.47 (0.87\u0026ndash;2.49)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.146\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.74 (1.27\u0026ndash;10.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.016\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNeutrophils (\u0026sdot;10\u003c/b\u003e\u003csup\u003e\u003cb\u003e9/\u003c/b\u003e\u003c/sup\u003e\u003cb\u003eL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (1.80\u0026ndash;6.30)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.05 (0.45\u0026ndash;2.46)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.905\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.08 (0.253\u0026ndash;4.632)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.915\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.93 (0.33\u0026ndash;2.58)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.884\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.42 (0.056\u0026ndash;3.132)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.398\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePlatelets (\u0026sdot;10\u003c/b\u003e\u003csup\u003e\u003cb\u003e9/\u003c/b\u003e\u003c/sup\u003e\u003cb\u003eL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (3.20\u0026ndash;7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.55 (0.70\u0026ndash;3.43)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.275\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.31 (0.31\u0026ndash;5.59)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.714\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.70 (0.10\u0026ndash;5.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.727\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.00 (0.00 - Inf)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.997\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLymphocytes (\u0026sdot;10\u003c/b\u003e\u003csup\u003e\u003cb\u003e9/\u003c/b\u003e\u003c/sup\u003e\u003cb\u003eL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (3.20\u0026ndash;7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.26 (1.34\u0026ndash;3.80)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e0.002\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.53 (1.85\u0026ndash;11.12)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e\u0026lt; 0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.90 (0.57\u0026ndash;6.27)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.295\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.49 (0.31\u0026ndash;20.21)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.394\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eC-reactive protein (mg/L)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (3.20\u0026ndash;7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.02 (0.28\u0026ndash;14.72)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.486\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.00 (0.00 - Inf)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.997\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePAR (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (3.20\u0026ndash;7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.85 (0.48\u0026ndash;1.49)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.561\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.31 (0.52\u0026ndash;3.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.569\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.93 (0.39\u0026ndash;2.22)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.875\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.88 (0.61\u0026ndash;5.84)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.273\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCholesterol (mmol/L)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (3.20\u0026ndash;7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.55 (0.56\u0026ndash;4.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.402\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.64 (0.09\u0026ndash;4.79)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.665\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.98 (0.46\u0026ndash;2.07)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.949\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.14 (0.34\u0026ndash;3.86)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.830\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTriglycerides (mmol/L)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (3.20\u0026ndash;7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.98 (0.46\u0026ndash;2.07)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.556\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.18 (0.52\u0026ndash;2.68)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.691\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHDL-C (mmol/L)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (3.20\u0026ndash;7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAbnormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.75 (0.42\u0026ndash;1.32)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.312\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.24 (0.53\u0026ndash;2.92)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.625\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLDL-C (mmol/L)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (3.20\u0026ndash;7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAbnormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0.29 (0.04\u0026ndash;2.11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0.222\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.92 (0.12\u0026ndash;6.85)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e0.938\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003eHBV: Hepatitis B virus; HCV: Hepatitis C virus; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; PAR: Platelet aggregation rate; CI: Confidence interval; c-TRAS: Confirmed TRAS; id-TRAS: Initially diagnosed TRAS; TRAS: Transplant renal artery stenosis.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab6\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 6\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMultivariable COX Regression Analysis of id-TRAS and c-TRAS\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eVariables\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eid-TRAS\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003ec-TRAS\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHR (95% CI)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eHR (95% CI)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAspirin\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003cp\u003e0.44 (0.26\u0026ndash;0.76)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e0.003\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003cp\u003e0.27 (0.10\u0026ndash;0.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.011\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAges\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026lt; 38\u003c/p\u003e \u003cp\u003e\u0026ge;\u0026thinsp;38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003cp\u003e1.91 (1.13\u0026ndash;3.22)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e0.015\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003cp\u003e2.84 (1.18\u0026ndash;6.81)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.020\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eStatins or not after transplantion\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003cp\u003e3.31 (1.89\u0026ndash;5.80)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e\u0026lt; 0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eUrea nitrogen (mmol/L)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (3.20\u0026ndash;7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003e0.037\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.17 (1.07\u0026ndash;9.41)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLymphocytes (\u0026sdot;10\u003c/b\u003e\u003csup\u003e\u003cb\u003e9/\u003c/b\u003e\u003c/sup\u003e\u003cb\u003eL)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal (3.20\u0026ndash;7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.00 (Reference)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.31 (1.36\u0026ndash;3.93)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e0.002\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.04 (1.63\u0026ndash;10.02)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.003\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.47 (0.69\u0026ndash;8.80)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0.163\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.31 (0.51\u0026ndash;36.56)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.180\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003ec-TRAS: Confirmed TRAS; HR: Hazard ratio; id-TRAS: Initially diagnosed TRAS; TRAS: Transplant renal artery stenosis; LDL-C: Low-density lipoprotein cholesterol; CI: Confidence interval.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eClinical adverse events\u003c/h2\u003e \u003cp\u003eThe difference in the total number of clinical adverse reactions and the incidence of haemorrhagic disorders between the two groups was statistically significant (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05).. There were no statistically significant differences between the two groups in terms of infarct disease, thrombotic disease, graft failure and mortality (\u003cem\u003eP\u003c/em\u003e \u0026gt; 0.05) [Table\u0026nbsp;\u003cspan refid=\"Tab7\" class=\"InternalRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab7\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 7\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eComparison of clinical adverse events among the kidney transplantation recipients between aspirin group and control group\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCharacteristic\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAspirin group (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;169)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eControl group (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;232)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eStatistical values\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTotal clinical adverse events, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e36 (21.30)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30 (12.93)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.98\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.026\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHemorrhagic diseases, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e27 (15.98)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19 (8.19)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.84\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.016\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGastrointestinal ulcer\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6 (22.22)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (26.32)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\" morerows=\"8\" rowspan=\"9\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"8\" rowspan=\"9\"\u003e \u003cp\u003e0.481\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGastrointestinal bleeding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3(11.11))\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (5.26\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eConjunctival hemorrhage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6 (22.22)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (5.26)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCerebral hemorrhage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (11.11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (10.53)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUterine bleeding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (14.81)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7 (36.84)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHematuria\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (7.41)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (5.26)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEpistaxis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (7.41)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0.00)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eThyroid bleeding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (5.26)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBronchorrhagia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (3.70)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (5.26)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eInfarct diseases, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7 (4.14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (2.59)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.385\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCerebral infarction\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (57.14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (83.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.559\u0026dagger;\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMyocardial infarction\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (42.86)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (16.67)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eThrombotic diseases, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (1.18)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (2.16)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.704\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVenous thrombosis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (100.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4 (80.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;0.999\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eArterial thrombosis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (20.00)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eGraft failure, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e19 (11.24)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22 (9.48)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.566\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eDeath, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (1.78)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10 (4.31)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.157\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003eValues are presented as numbers (%). \u0026dagger;Refers to Fisher\u0026rsquo;s exact test, others were tested by Pearson χ2 test.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eLaboratory indicators\u003c/h2\u003e \u003cp\u003eThe differences in creatinine, urea nitrogen, neutrophils, platelets, lymphocytes, C-reactive protein,, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were not statistically significant in the two groups at 3 months after kidney transplantation (\u003cem\u003eP\u003c/em\u003e \u0026gt; 0.05). The two groups showed statistically significant differences in both the Platelet aggregation rate (PAR) and cholesterol levels. (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05) [Table\u0026nbsp;\u003cspan refid=\"Tab8\" class=\"InternalRef\"\u003e8\u003c/span\u003e].\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab8\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 8\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eComparison of laboratory indicators of the kidney transplantation recipients at 3 months after renal transplantation\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVariables\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAspirin group (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;169)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eControl group (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;232)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eStatistical values\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCreatinine, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.188\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e142 (84.02)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e185 (79.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.59)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e26 (15.39)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e47 (20.26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eUrea nitrogen, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.277\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e68 (40.24)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e106 (45.69)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e101 (59.76)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e126 (54.31)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNeutrophils, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.764\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.414\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e136 (80.47)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e196 (84.48)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e16 (9.47)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14 (6.03)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e17 (10.06)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22 (9.48)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePlatelets, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.667\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e155 (91.72)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e211 (90.95)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e12 (7.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15 (6.47)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (1.18)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (2.59)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLymphocytes, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.259\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.119\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e99 (58.58)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e159 (68.53)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e63 (37.28)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e65 (28.02)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7 (4.14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8 (3.45)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eC-reactive protein, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.000\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e168 (99.41)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e230 (99.14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.59)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (0.86)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePAR, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e50.01\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e\u0026lt; 0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e88 (52.07)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e158 (68.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e75 (44.38)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35 (15.09)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6 (3.55)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39 (16.81)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eCholesterol, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9.736\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e0.008\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e150 (88.76)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e178 (76.72)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8 (4.73)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19 (8.19)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11 (6.51)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35 (15.09)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTriglycerides, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.586\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.444\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e99 (58.58)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e127 (54.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHigh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e70 (41.42)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e105 (45.26)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHDL-C, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.216\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.270\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e113 (66.86)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e167 (71.98)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAbnormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e56 (33.14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e65 (28.02)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eLDL-C, n (%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.639\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.056\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e165 (97.63)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e217 (93.53)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAbnormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (2.37)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15 (6.47)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003eContinuous variables are presented as median (interquartile range) or mean \u0026plusmn; standard deviation. \u003csup\u003e\u0026dagger;\u003c/sup\u003eRefers to Fisher\u0026rsquo;s exact test, others were tested by Pearson χ2 test. PAR: Platelet aggregation rate; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis study aimed to investigate the impact of age on the preventive efficacy of low-dose aspirin against TRAS. Although a previous prospective randomized controlled trial suggested that postoperative low-dose aspirin may reduce the risk of TRAS, the extent to which this preventive effect varies with age has not been clearly defined.\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e Therefore, we conducted a retrospective analysis with stringent inclusion and exclusion criteria to further explore this question. Given the retrospective, non-randomized design and potential for residual confounding, the observed associations should be interpreted cautiously as hypothesis-generating rather than definitive evidence of causality.\u003c/p\u003e \u003cp\u003eIn the present study, there were no significant differences in baseline characteristics between the two groups, except for renal artery anastomosis and graft type. In the subsequent univariate analysis, we found that deceased donor kidney was a risk factor for id-TRAS but not for c-TRAS, and renal arterial anastomosis was not a significant risk factor for TRAS (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026gt;\u0026thinsp;0.05).Previous studies have shown that the risk of TRAS is higher in deceased-donor kidney transplantation than in living-donor kidney transplantation.\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e However, baseline data indicated a higher rate of cadaveric transplantation in the aspirin group compared to the control group (61.54% vs 43.10%), yet the incidence of TRAS was lower in the aspirin group. This finding may indicate that aspirin plays a role in preventing and managing TRAS. Although there was no statistically significant difference in the incidence of id-TRAS between the two groups, the incidence of c-TRAS was significantly lower in the aspirin group than in the control group (2.96% vs 7.76%, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.041), and patients with TRAS in the control group exhibited more severe luminal stenosis (P\u0026thinsp;=\u0026thinsp;0.037). This further confirms that low-dose aspirin use is associated with a reduced incidence of c-TRAS, consistent with our previous findings..\u003csup\u003e28\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eFurthermore, we classified the study subjects in both the aspirin and control groups into age subgroups (\u0026lt; 38 years and \u0026ge;\u0026thinsp;38 years). In subgroup analysis, after controlling for the effect of aspirin, significant differences were observed in the incidence rates of id-TRAS (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.001) and c-TRAS (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001) across different age groups, suggesting that age may influence the efficacy of aspirin in preventing TRAS. Survival curves revealed that patients aged\u0026thinsp;\u0026ge;\u0026thinsp;38 years had a higher cumulative risk of id-TRAS regardless of aspirin use, while those aged \u0026lt; 38 years who took aspirin had the lowest cumulative risk, with statistically significant differences between groups (log-rank \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.016). Survival analysis for c-TRAS patients revealed the lowest cumulative risk among aspirin users aged \u0026lt; 38 years and the highest cumulative risk among non-aspirin users aged\u0026thinsp;\u0026ge;\u0026thinsp;38 years, with a statistically significant difference between groups (log-rank \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.006). This further indicates that age is a key factor influencing aspirin efficacy.\u003c/p\u003e \u003cp\u003eGiven the limited number of c-TRAS events, the multivariable estimates for this outcome should be interpreted with caution due to potential model overfitting. Further univariate and multivariate analyses revealed that non-aspirin use, age\u0026thinsp;\u0026ge;\u0026thinsp;38 years, cadaveric transplantation, statin use, and low lymphocyte count were risk factors for id-TRAS. Age\u0026thinsp;\u0026ge;\u0026thinsp;38 years, elevated blood urea nitrogen, and low lymphocyte count were risk factors for c-TRAS. Multivariate Cox regression analysis revealed that aspirin use was associated with a reduced risk of TRAS. In contrast, several factors were identified as significant risk predictors for TRAS, including age\u0026thinsp;\u0026ge;\u0026thinsp;38 years, statin use, elevated blood urea nitrogen levels, and low lymphocyte counts. These findings suggest that while aspirin may offer a protective effect, other clinical variables, particularly those associated with kidney function and immune status, play crucial roles in determining TRAS risk. However, further research is needed to validate these associations and explore potential interactions between these factors in different patient populations. Patients receiving statins often have vascular plaques, advanced age, dyslipidemia, or a history of cardiovascular or cerebrovascular disease, potentially contributing to higher TRAS incidence.\u003c/p\u003e \u003cp\u003eWhile aspirin has well-established benefits in preventing thrombosis, its use may increase the risk of hemorrhagic events, particularly gastrointestinal bleeding, and this risk is higher in older patients\u003csup\u003e\u003cspan additionalcitationids=\"CR39 CR40\" citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u003c/sup\u003e. Clinical trials have reported an increased risk of bleeding with low-dose aspirin therapy\u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e,\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u003c/sup\u003e. These findings underscore the importance of carefully weighing the potential benefits and risks of aspirin use, especially in older patients. The decision to initiate aspirin therapy should be individualized, considering factors such as the patient\u0026rsquo;s underlying health, type of disease, and concurrent medications.. Our findings indicate that patients in the aspirin group experienced a higher incidence of bleeding-related clinical events compared to the control group (15.98% vs 8.19%, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.016). Additionally, the aspirin group exhibited a higher overall incidence of clinical adverse events (21.30% vs 12.93%, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.026), consistent with previous literature findings. However, this contradicts our earlier prospective study\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e, likely due to differences in enrollment periods and modifications to inclusion/exclusion criteria. Consequently, the benefits and risks of aspirin use in different renal transplant populations require comprehensive evaluation. When determining aspirin therapy, patient age, medical history, and a thorough risk-benefit assessment must be considered holistically. Significant differences were observed between the aspirin group and the control group at 3 months post-transplantation in terms of arachidonic acid-induced platelet aggregation rate (\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.001) and cholesterol levels (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.008). consistent with findings from our prior prospective study\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. It is hypothesized that aspirin may prevent TRAS by partially inhibiting microthrombus formation through anticoagulation and by preventing atherosclerosis via lipid profile improvement.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eIn this single-center cohort, administering low-dose aspirin post-transplant was associated with a lower incidence of c-TRAS, with the most pronounced protective effect observed in recipients aged \u0026lt; 38 years. However, aspirin use was also associated with an increased risk of bleeding, emphasizing the need for individualized risk-benefit evaluation.\u003c/p\u003e "},{"header":"Limitations","content":"\u003cp\u003eThe main limitations of this study include its retrospective nature, the potential for unmeasured confounding factors, and the single-center design. Furthermore, the sample size was limited, and future validation with larger, multicenter studies is necessary to confirm these findings.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eESRD\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eend-stage renal disease\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eTRAS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003etransplant renal artery stenosis\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eNSAID\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003enonsteroidal anti-inflammatory drug\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eROS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ereactive oxygen species\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eNO\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003enitric oxide\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eROC\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ereceiver operating characteristic\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDUS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eDoppler ultrasound\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eid-TRAS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003einitially diagnosed TRAS\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003ePSA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003epeak systolic velocity\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDSA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003edigital subtraction angiography\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003ec-TRAS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003econfirmed TRAS\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eATG\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eanti-thymocyte globulin\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eMMF\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003emycophenolate mofetil\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eMPS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003emycophenolate sodium\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eCTA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ecomputed tomography angiography\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eMRA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003emagnetic resonance angiography\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003ePTA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003epercutaneous transluminal angioplasty\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eHBV\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eHepatitis B virus\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eHCV\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eHepatitis C virus\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eHR\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eHazard ratio\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003ePAR\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003ePlatelet aggregation rate\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eLDL-C\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003elow-density lipoprotein cholesterol\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eLDL-C: Low-density lipoprotein cholesterol..\u003c/div\u003e \u003cdiv class=\"Description\"\u003e\u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e \u003ch2\u003eEthics approval and consent to participate\u003c/h2\u003e \u003cp\u003e The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Henan Provincial People\u0026rsquo;s Hospital. Given the retrospective nature and use of anonymized data, informed consent was waived by the Ethics Committee.\u003c/p\u003e \u003c/p\u003e\u003cp\u003e \u003ch2\u003eTransplantation studies statement\u003c/h2\u003e \u003cp\u003e All transplanted organs were obtained from voluntary donors with informed consent, in accordance with the relevant national and international regulations. No organs or tissues were procured from prisoners. The kidneys were procured from donors via the China Organ Transplantation Response System, and transplantations were performed at Henan Provincial People\u0026rsquo;s Hospital, Zhengzhou, China.\u003c/p\u003e \u003c/p\u003e\u003cp\u003e \u003ch2\u003eConsent for publication\u003c/h2\u003e \u003cp\u003eNot applicable.\u003c/p\u003e \u003c/p\u003e\u003cp\u003e \u003ch2\u003eCompeting interests\u003c/h2\u003e \u003cp\u003eThe authors declare that there are no competing interests associated with the manuscript.\u003c/p\u003e \u003c/p\u003e\u003cp\u003e \u003ch2\u003eCRediT Author Contribution\u003c/h2\u003e \u003cp\u003eX.T., X.L., T.Y., and T.Q.: Conceptualization. W.D. and J.Z.: Methodology. X.W., G.C., X.J., Z.W., X.W., C.Z., Z.Y., and X.F.: Investigation. J.Z., X.T., X.L., and W.D.: Visualization. X.T. and X.L.: Writing\u0026mdash;original draft. X.T., X.L., W.D., Q.L., and Q.F.: Writing\u0026mdash;review \u0026amp; editing. X.T., X.J., and T.Y.: Funding acquisition. T.Y. and T.Q.: Supervision.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFunding\u003c/h2\u003e \u003cp\u003eThis work was supported by the Project of Science and Technology of Henan Province (Grant No. 232102310157), the Joint construction project of Henan Medical Science and technology research plan (Grant No. LHGJ20240029), the natural Science Foundation of Henan Province of China (Grant No. 242300421301), the Henan Province Medical Science and Technology Research (Joint Construction) Project (Grant No. LHG20220781).\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eX.T., X.L., T.Y., and T.Q.: Conceptualization. W.D. and J.Z.: Methodology. X.W., G.C., X.J., Z.W., X.W., C.Z., Z.Y., and X.F.: Investigation. J.Z., X.T., X.L., and W.D.: Visualization. X.T. and X.L.: Writing\u0026mdash;original draft. X.T., X.L., W.D., Q.L., and Q.F.: Writing\u0026mdash;review \u0026amp;amp; editing. X.T., X.J., and T.Y.: Funding acquisition. T.Y. and T.Q.: Supervision.\u003c/p\u003e\u003ch2\u003eAcknowledgements\u003c/h2\u003e \u003cp\u003eNot applicable.\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003eData from this study are available from the authors upon reasonable request. Please contact [email protected] to request data. Access to data may be subject to approval, confidentiality and ethical conditions.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eHariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. N Engl J Med Aug. 2021;19(8):729\u0026ndash;43. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMra2014530\u003c/span\u003e\u003cspan address=\"10.1056/NEJMra2014530\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med Dec. 1999;2(23):1725\u0026ndash;30. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/nejm199912023412303\u003c/span\u003e\u003cspan address=\"10.1056/nejm199912023412303\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMargules RM, Belzer FO, Kountz SL. Surgical correction of renovascular hypertension following renal allotransplantation. Arch Surg Jan. 1973;106(1):13\u0026ndash;6. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/archsurg.1973.01350130017003\u003c/span\u003e\u003cspan address=\"10.1001/archsurg.1973.01350130017003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBiederman DM, Fischman AM, Titano JJ, et al. Tailoring the endovascular management of transplant renal artery stenosis. Am J Transplant Apr. 2015;15(4):1039\u0026ndash;49. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ajt.13105\u003c/span\u003e\u003cspan address=\"10.1111/ajt.13105\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBruno S, Remuzzi G, Ruggenenti P. Transplant renal artery stenosis. J Am Soc Nephrol Jan. 2004;15(1):134\u0026ndash;41. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/01.asn.0000099379.61001.f8\u003c/span\u003e\u003cspan address=\"10.1097/01.asn.0000099379.61001.f8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCarpenter DJ, Mohan S, Ratner LE, Schlossberg P. Combined Percutaneous Transrenal and Transfemoral Endovascular Recanalization and Angioplastic Reconstruction of a Disrupted Transplant Renal Artery Stent: A Novel Salvage Technique. Am J Transplant Apr. 2017;17(4):1119\u0026ndash;24. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ajt.14115\u003c/span\u003e\u003cspan address=\"10.1111/ajt.14115\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHurst FP, Abbott KC, Neff RT, et al. Incidence, predictors and outcomes of transplant renal artery stenosis after kidney transplantation: analysis of USRDS. Am J Nephrol. 2009;30(5):459\u0026ndash;67. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1159/000242431\u003c/span\u003e\u003cspan address=\"10.1159/000242431\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWillicombe M, Sandhu B, Brookes P, et al. Postanastomotic transplant renal artery stenosis: association with de novo class II donor-specific antibodies. Am J Transplant Jan. 2014;14(1):133\u0026ndash;43. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ajt.12531\u003c/span\u003e\u003cspan address=\"10.1111/ajt.12531\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAubert O, Kamar N, Vernerey D, et al. Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. Bmj Jul. 2015;31:351:h3557. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/bmj.h3557\u003c/span\u003e\u003cspan address=\"10.1136/bmj.h3557\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAudard V, Matignon M, Hemery F, et al. Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty. Am J Transplant Jan. 2006;6(1):95\u0026ndash;9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1600-6143.2005.01136.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1600-6143.2005.01136.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBraga AF, Catto RC, Dalio MB, et al. Endovascular Approach to Transplant Renal Artery Stenosis. Ann Transplant Nov. 2015;24:20:698\u0026ndash;706. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.12659/aot.894867\u003c/span\u003e\u003cspan address=\"10.12659/aot.894867\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKamali K, Abbasi MA, Behzadi AH, Mortazavi A, Bastani B. Incidence and risk factors of transplant renal artery stenosis in living unrelated donor renal transplantation. J Ren Care Sep. 2010;36(3):149\u0026ndash;52. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/j.1755-6686.2010.00188.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1755-6686.2010.00188.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKobayashi K, Censullo ML, Rossman LL, Kyriakides PN, Kahan BD, Cohen AM. Interventional radiologic management of renal transplant dysfunction: indications, limitations, and technical considerations. Radiographics Jul-Aug. 2007;27(4):1109\u0026ndash;30. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1148/rg.274065135\u003c/span\u003e\u003cspan address=\"10.1148/rg.274065135\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMartelli E, Enea I, Zamboni M, et al. Focus on the Most Common Paucisymptomatic Vasculopathic Population, from Diagnosis to Secondary Prevention of Complications. Diagnostics (Basel) Jul. 2023;13(14). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/diagnostics13142356\u003c/span\u003e\u003cspan address=\"10.3390/diagnostics13142356\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYang S, Kang J, Park KW, et al. Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks. J Am Coll Cardiol Oct. 2023;17(16):1565\u0026ndash;78. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jacc.2023.07.031\u003c/span\u003e\u003cspan address=\"10.1016/j.jacc.2023.07.031\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNasserala JC, Oliveira CM, Cerqueira JB et al. Artery Stenosis of the Renal Graft: Experience of a Center of Northeastern Brazil. \u003cem\u003eTransplant Proc\u003c/em\u003e. Jan-Feb. 2016;48(1):74\u0026ndash;80. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.transproceed.2015.11.004\u003c/span\u003e\u003cspan address=\"10.1016/j.transproceed.2015.11.004\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eElmously A, Stern JR, Greenberg J, et al. Carbon Dioxide Angiography in the Treatment of Transplant Renal Artery Stenosis. Ann Vasc Surg Feb. 2020;63:198\u0026ndash;203. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.avsg.2019.08.085\u003c/span\u003e\u003cspan address=\"10.1016/j.avsg.2019.08.085\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGaddikeri S, Mitsumori L, Vaidya S, Hippe DS, Bhargava P, Dighe MK. Comparing the diagnostic accuracy of contrast-enhanced computed tomographic angiography and gadolinium-enhanced magnetic resonance angiography for the assessment of hemodynamically significant transplant renal artery stenosis. Curr Probl Diagn Radiol Jul-Aug. 2014;43(4):162\u0026ndash;8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1067/j.cpradiol.2014.03.001\u003c/span\u003e\u003cspan address=\"10.1067/j.cpradiol.2014.03.001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNicholson ML, Yong C, Trotter PB, Grant L, Hosgood SA. Risk factors for transplant renal artery stenosis after live donor transplantation. Br J Surg Feb. 2019;106(3):199\u0026ndash;205. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/bjs.10997\u003c/span\u003e\u003cspan address=\"10.1002/bjs.10997\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRobinson KA, Kriegshauser JS, Dahiya N, Young SW, Czaplicki CD, Patel MD. Detection of transplant renal artery stenosis: determining normal velocities at the renal artery anastomosis. Abdom Radiol (NY) Jan. 2017;42(1):254\u0026ndash;9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00261-016-0876-7\u003c/span\u003e\u003cspan address=\"10.1007/s00261-016-0876-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAghayev A, Memon AA, Zheng S, Menard M, Siedlecki AM. Transplant renal artery and vein occlusion evaluated with ferumoxytol-enhanced magnetic resonance angiography. Clin Imaging Sep. 2021;77:142\u0026ndash;6. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.clinimag.2021.02.022\u003c/span\u003e\u003cspan address=\"10.1016/j.clinimag.2021.02.022\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVisagie JL, Aruwajoye GS, van der Sluis R. Pharmacokinetics of aspirin: evaluating shortcomings in the literature. Expert Opin Drug Metab Toxicol Aug. 2024;20(8):727\u0026ndash;40. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1080/17425255.2024.2386368\u003c/span\u003e\u003cspan address=\"10.1080/17425255.2024.2386368\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. Jan 2021;21(3):216\u0026ndash;28. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMoa2028220\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa2028220\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChang H, Gelb BE, Stewart ZA, et al. Safety and Efficacy of Drug Eluting Stents for Treatment of Transplant Renal Artery Stenosis. Ann Vasc Surg Nov. 2022;87:245\u0026ndash;53. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.avsg.2022.03.033\u003c/span\u003e\u003cspan address=\"10.1016/j.avsg.2022.03.033\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDickey KW, Durrani RJ. Does Endovascular Intervention for Transplant Renal Artery Stenosis Improve Outcomes at 10 Years? Radiology Feb. 2019;290(2):564\u0026ndash;5. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1148/radiol.2018182252\u003c/span\u003e\u003cspan address=\"10.1148/radiol.2018182252\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHinojosa-Gonzalez DE, Salgado-Garza G, Torres-Martinez M, et al. Endovascular Treatment of Transplant Renal Artery Stenosis: A Systematic Review and Meta-analysis. J Endovasc Ther Apr. 2022;29(2):294\u0026ndash;306. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1177/15266028211038593\u003c/span\u003e\u003cspan address=\"10.1177/15266028211038593\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePatel U, Kumar S, Johnson OW, Jeon JH, Das R. Long-term Graft and Patient Survival after Percutaneous Angioplasty or Arterial Stent Placement for Transplant Renal Artery Stenosis: A 21-year Matched Cohort Study. Radiology Feb. 2019;290(2):555\u0026ndash;63. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1148/radiol.2018181320\u003c/span\u003e\u003cspan address=\"10.1148/radiol.2018181320\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTian X, Ji B, Niu X et al. Efficacy and safety of low-dose aspirin on preventing transplant renal artery stenosis: a prospective randomized controlled trial. \u003cem\u003eChin Med J (Engl)\u003c/em\u003e. Mar 5. 2023;136(5):541\u0026ndash;549. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/cm9.0000000000002574\u003c/span\u003e\u003cspan address=\"10.1097/cm9.0000000000002574\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCevenini E, Monti D, Franceschi C. Inflamm-ageing. Curr Opin Clin Nutr Metab Care Jan. 2013;16(1):14\u0026ndash;20. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/MCO.0b013e32835ada13\u003c/span\u003e\u003cspan address=\"10.1097/MCO.0b013e32835ada13\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSch\u0026ouml;ttker B, Saum KU, Jansen EH, et al. Oxidative stress markers and all-cause mortality at older age: a population-based cohort study. J Gerontol Biol Sci Med Sci Apr. 2015;70(4):518\u0026ndash;24. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/gerona/glu111\u003c/span\u003e\u003cspan address=\"10.1093/gerona/glu111\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEl-Mahdy MA, Abdelghany TM, Hemann C, et al. Chronic cigarette smoke exposure triggers a vicious cycle of leukocyte and endothelial-mediated oxidant stress that results in vascular dysfunction. Am J Physiol Heart Circ Physiol. Jul 2020;1(1):H51\u0026ndash;65. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1152/ajpheart.00657.2019\u003c/span\u003e\u003cspan address=\"10.1152/ajpheart.00657.2019\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKawaguchi Y, Kuwana M. Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis. Curr Opin Rheumatol Nov. 2023;1(6):309\u0026ndash;16. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/bor.0000000000000959\u003c/span\u003e\u003cspan address=\"10.1097/bor.0000000000000959\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUngvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of Vascular Aging. Circ Res Sep. 2018;14(7):849\u0026ndash;67. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1161/circresaha.118.311378\u003c/span\u003e\u003cspan address=\"10.1161/circresaha.118.311378\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePan FS, Liu M, Luo J, et al. Transplant renal artery stenosis: Evaluation with contrast-enhanced ultrasound. Eur J Radiol May. 2017;90:42\u0026ndash;9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ejrad.2017.02.031\u003c/span\u003e\u003cspan address=\"10.1016/j.ejrad.2017.02.031\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWongpraparut N, Chaipruckmalakarn T, Tongdee T, et al. Long-term outcome of percutaneous transluminal renal angioplasty (PTRA) versus PTRA with stenting (PTRAS) in transplant renal artery stenosis. BMC Cardiovasc Disord Apr. 2021;26(1):212. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s12872-021-02015-4\u003c/span\u003e\u003cspan address=\"10.1186/s12872-021-02015-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGunawardena T, Sharma H. Transplant Renal Artery Stenosis: Current Concepts. Exp Clin Transplant Dec. 2022;20(12):1049\u0026ndash;57. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.6002/ect.2022.0334\u003c/span\u003e\u003cspan address=\"10.6002/ect.2022.0334\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBarnett HJM, Taylor DW, Haynes RB, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med Aug. 1991;15(7):445\u0026ndash;53. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/nejm199108153250701\u003c/span\u003e\u003cspan address=\"10.1056/nejm199108153250701\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMahady SE, Margolis KL, Chan A, et al. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut Apr. 2021;70(4):717\u0026ndash;24. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/gutjnl-2020-321585\u003c/span\u003e\u003cspan address=\"10.1136/gutjnl-2020-321585\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med Oct. 2018;18(16):1509\u0026ndash;18. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMoa1805819\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa1805819\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOrkaby AR, Dufour AB, Yang L, et al. Long-Term Aspirin Use and Self-Reported Walking Speed in Older Men: The Physicians' Health Study. J Frailty Aging. 2022;11(1):12\u0026ndash;7. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.14283/jfa.2021.36\u003c/span\u003e\u003cspan address=\"10.14283/jfa.2021.36\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang FM, Yebyo HG, Ballew SH, et al. Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention. Am J Prev Cardiol Mar. 2023;13:100468. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ajpc.2023.100468\u003c/span\u003e\u003cspan address=\"10.1016/j.ajpc.2023.100468\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcQuilten ZK, Thao LTP, Pasricha SR, et al. Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly: A Secondary Analysis of the Aspirin in Reducing Events in the Elderly Trial. Ann Intern Med. Jul 2023;176(7):913\u0026ndash;21. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7326/m23-0675\u003c/span\u003e\u003cspan address=\"10.7326/m23-0675\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZoungas S, Zhou Z, Owen AJ, et al. Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial. Lancet Diabetes Endocrinol Feb. 2024;12(2):98\u0026ndash;106. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s2213-8587(23)00327-3\u003c/span\u003e\u003cspan address=\"10.1016/s2213-8587(23)00327-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-nephrology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bnep","sideBox":"Learn more about [BMC Nephrology](http://bmcnephrol.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bnep/default.aspx","title":"BMC Nephrology","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Kidney transplantation, Transplant renal artery stenosis, Aspirin","lastPublishedDoi":"10.21203/rs.3.rs-8822867/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8822867/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eTransplant renal artery stenosis (TRAS) is a potentially serious complication following kidney transplantation. Low-dose aspirin has been proposed as a preventive strategy due to its antiplatelet and vascular protective effects. In this study, we retrospectively analyzed kidney transplant recipients at our center from January 2018 to December 2021. Patients were categorized into an aspirin group (n = 169) and a control group (n = 232). Initially diagnosed TRAS (id-TRAS) was diagnosed by Doppler ultrasound; confirmed TRAS (c-TRAS) by digital subtraction angiography. Id-TRAS incidence was similar between groups (14.20% vs. 15.95%), but c-TRAS was significantly lower with aspirin (2.96% vs. 7.76%; P = 0.041). ROC analysis identified 38 years as the optimal cutoff for TRAS risk,and patients were divided into two groups: ＜ 38 years and ≥ 38 years.After controlling for ages, the incidence of c-TRAS showed a statistically significant difference (P = 0.028). After controlling for aspirin use, the incidence rates of id-TRAS and c-TRAS differed significantly across age groups (P = 0.001; P ＜ 0.001). Kaplan-Meier analysis demonstrated that patients aged ＜ 38 years receiving aspirin had the lowest cumulative risk for both id-TRAS and c-TRAS, with statistically significant intergroup differences (log-rank P = 0.016; P = 0.006). Univariate Cox regression identified several risk factors for TRAS. Subsequent multivariate Cox regression revealed that aspirin use reduced the risk of id-TRAS and c-TRAS by 56% (HR = 0.44, 95% CI: 0.26 - 0.76, P = 0.003) and 73% (HR = 0.27, 95% CI: 0.10 - 0.74, P = 0.011), respectively. In contrast, age ≥ 38 years conferred a 1.91-fold and 2.84-fold increased risk for id-TRAS (HR = 1.91, 95% CI: 1.13 - 3.22, P = 0.015) and c-TRAS (HR = 2.84, 95% CI: 1.18 - 6.81, P = 0.020). Bleeding events were more frequent in the aspirin group (P = 0.016), with lower platelet aggregation at 3 months (P ＜ 0.001). In conclusion, low-dose aspirin appears to lower the incidence of c-TRAS, especially in younger recipients, while predisposing older patients to a higher risk of bleeding. These results emphasize the importance of individualized risk-benefit evaluation in clinical decision-making.\u003c/p\u003e","manuscriptTitle":"Aspirin for the Prevention of Transplant Renal Artery Stenosis: The Role of Age Factor","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-03-08 14:47:53","doi":"10.21203/rs.3.rs-8822867/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"editorInvitedReview","content":"","date":"2026-05-07T08:32:29+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"191289107441401877402383693600047938523","date":"2026-05-06T14:00:04+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"93264331629849830988948657618317945887","date":"2026-04-13T16:53:29+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2026-02-26T09:54:44+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2026-02-24T05:46:52+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2026-02-16T15:13:23+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2026-02-15T14:12:49+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Nephrology","date":"2026-02-15T14:05:14+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-nephrology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bnep","sideBox":"Learn more about [BMC Nephrology](http://bmcnephrol.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bnep/default.aspx","title":"BMC Nephrology","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"96a017b0-d3ec-4c8f-aeb9-e5a2a189fbce","owner":[],"postedDate":"March 8th, 2026","published":true,"recentEditorialEvents":[{"type":"editorInvitedReview","content":"","date":"2026-05-07T08:32:29+00:00","index":76,"fulltext":""},{"type":"reviewerAgreed","content":"191289107441401877402383693600047938523","date":"2026-05-06T14:00:04+00:00","index":75,"fulltext":""}],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2026-03-08T14:47:53+00:00","versionOfRecord":[],"versionCreatedAt":"2026-03-08 14:47:53","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8822867","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8822867","identity":"rs-8822867","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}